



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07C 315/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/44316</b> <b>(43) International Publication Date:</b> 27 November 1997 (27.11.97)
<b>(21) International Application Number:</b> PCT/US97/08593 <b>(22) International Filing Date:</b> 21 May 1997 (21.05.97) <b>(30) Priority Data:</b> 08/651,819                      21 May 1996 (21.05.96)                      US <b>(71) Applicant:</b> THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, La Jolla, CA 92037 (US). <b>(72) Inventors:</b> SHARPLESS, K., Barry; 7902 Roseland Drive, La Jolla, CA 92037 (US). LI, Guigen; 8450-D Via Mallorca, La Jolla, CA 92037 (US). CHANG, Han-Ting; 12550 Carmel Creek Road No. 93, San Diego, CA 92130 (US). <b>(74) Agent:</b> LEWIS, Donald, G.; The Scripps Research Institute, 10550 North Torrey Pines Road, TPC-8, La Jolla, CA 92037 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the          claims and to be republished in the event of the receipt of          amendments.</i>
<b>(54) Title:</b> CATALYTIC ASYMMETRIC AMINOHYDROXYLATION OF OLEFINS WITH SULFONAMIDES <b>(57) Abstract</b> <p><math>\beta</math>-Hydroxyamines and <math>\beta</math>-hydroxysulfonamides are synthesized from olefin substrates by means of a catalyzed asymmetric addition reaction. The addition reaction is catalyzed by osmium and is co-catalyzed by chiral ligands. The chiral ligands, in addition to being co-catalysts with the osmium, also serve to direct the addition reaction regioselectively and enantioselectively. Divalent ligands are preferred over monovalent ligands because of their enhanced regio- and enantio-selectivity. Sulfonamides are employed as an oxidant nitrogen source for the production of <math>\beta</math>-hydroxysulfonamides. Excellent yields and enantiomeric efficiencies are achieved with co-solvents containing a 50/50 (v/v) mixtures of water and organic solvent. <math>\beta</math>-Hydroxyamines are obtained by deprotecting the corresponding <math>\beta</math>-hydroxysulfonamides.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

CATALYTIC ASYMMETRIC AMINOHYDROXYLATION  
OF OLEFINS WITH SULFONAMIDES

Specification

5     Field of Invention:

          The invention relates to the regio-selective and enantio-selective conversion of olefins to  $\beta$ -hydroxyamines and  $\beta$ -hydroxysulfonamides. More particularly, the invention relates to catalytic asymmetric additions or aminohydroxylations of olefins and other unsaturated substrates using sulfonamide as an oxidizing agent in the presence of an osmium catalyst and a chiral ligand.

15     Background:

          The  $\beta$ -hydroxyamine group is a common motif found in biologically active molecules. For example, the C-13 side-chain of taxol includes a  $\beta$ -hydroxyamine group and is known to be essential for the biological activity of taxol. Hence synthesis of the side-chain and its analogs is a subject of significant recent interest. Modifications of the taxol side-chain are an important aspect of the structure-activity-relationship (SAR). Among numerous synthetic approaches, the asymmetric catalytic methods hold special interest. The catalytic asymmetric dihydroxylation (AD) and asymmetric epoxidation (AE) have been successfully applied in syntheses of the C-13 side-chain. (Denis, J.-N., et al., Journal of Organic Chemistry, 51(1986) 46; Denis, J.-N., et al., Journal of Organic Chemistry, 55(1990) 1957; Deng, L. and

- 2 -

Jacobsen, E. N.. Journal of Organic Chemistry, 57(1992) 4320; and Wang, Z.-M., et al., Journal of Organic Chemistry, 59(1994) 5104).

5       Sharpless et al. first demonstrated that  $\beta$ -hydroxysulfonamides could be obtained using either stoichiometric or catalytic amounts of 1% osmium tetraoxide in the presence of 1.5 - 5 equivalents of Chloramine-T trihydrate ( $\text{TsSO}_2\text{NClNa} \cdot 3\text{H}_2\text{O}$ , Ts = tosylate; commercially obtained) to effect cis addition of a  
10       hydroxyl (OH) and an arylsulfonamide moiety ( $\text{Ar-SO}_2\text{NH}$ ) across a mono or disubstituted olefinic linkages (Sharpless et. al. *J. Org. Chemistry* **1976**, 41, 177).

Two procedures were developed to effect hydroxyamination of olefins using sulfonamides.  
15       (Sharpless et al. *Org. Syn.* **1980**, 61, 85). The first procedure used phase transfer catalysis conditions at 55-60 °C with 1%  $\text{OsO}_4$ , 1:1 v/v, 0.20 Molar  $\text{CHCl}_3/\text{H}_2\text{O}$ , and benzyltriethylammonium chloride as the phase transfer catalyst. The chloramine T-trihydrate  
20       ( $\text{TsSO}_2\text{NClNa} \cdot 3\text{H}_2\text{O}$ ) was either added directly or formed in situ in water; this solution was then directly used in the phase transfer mixture. The in situ procedure, for generating the chloramine salts, involved stirring a suspension of the arylsulfonamide with an equivalent of  
25       sodium hypochlorite (Clorox) until a homogenous solution was obtained. The yields were comparable with those obtained with isolated chloramine salts and the procedure was found most effective for monosubstituted, and 1,2 disubstituted olefins. The phase transfer  
30       method, however, gave poor results with trisubstituted

- 3 -

and 1,1-disubstituted olefins and the procedure did not succeed with diethyl fumarate and 2-cyclohexen-1-one. Sharpless et al. *J. Org. Chem.* **1978**, 43, 2544.

5 A second procedure was carried out in tert-butyl alcohol at 55- 60 °C with 1% OsO<sub>4</sub>, silver nitrate (with or without) and commercially obtained chloramine T-trihydrate (TsSO<sub>2</sub>NClNa·3H<sub>2</sub>O) which provided the only source of water. The procedure did not succeed with tetramethylethylene and cholesterol, and negative  
10 results were found with most hindered tri- and tetrasubstituted olefins. Sharpless et. al. *J. Org. Chemistry* **1976**, 41, 177; Sharpless et al. *Org. Syn.* **1980**, 61, 85. The addition of divalent metal salts such as AgNO<sub>3</sub> and Hg(NO<sub>3</sub>)<sub>2</sub> improved some reactions, however,  
15 other reactions suffered deleterious effects from the addition of the metal salts. Sharpless et al. *J. Org. Chem.* **1978**, 43, 2544; Sharpless et. al. *J. Org. Chemistry* **1976**, 41, 177.

Further elaboration on either procedure showed  
20 that other sulfonamide derivatives (ArSO<sub>2</sub>NClNa) could be successfully employed in addition to chloramine T, where Ar = phenyl, o-tolyl, p-chlorophenyl, p-nitrophenyl, and o-carboalkoxyphenyl. Sharpless et al. *J. Org. Chem.* **1978**, 43, 2546.

25 Neither the phase transfer catalyst or tert-butyl alcohol procedures succeeded with tetramethyl ethylene, 2,3-dimethyl-2-octene, diethyl fumarate, or 2-cyclohexen-1-one. Negative results were also obtained with most hindered tri- and tetrasubstituted olefins.  
30 Herranz E., MIT Ph.D. Thesis, **1979**, 33.

- 4 -

Solvent conditions for the synthesis of the hydroxysulfonamides included organic solvents such as acetonitrile, *tert*-butyl alcohol, isopropyl alcohol and chloroform which was in contact with the aqueous phase in the phase transfer catalyst procedure.

The *tert*-butyl alcohol procedure (including other solvents used) was not run with added water; the phase transfer catalyst (PTC) procedure required a biphasic mixture of 1:1 v/v chloroform/water. Recently, however, an improvement was reported which used a 1:1 ratio of organic solvent to water in a homogeneous, rather than a biphasic solution or organic solvent with small amounts of water. These conditions were found to provide optimum enantioselectivity, regioselectivity and improved yields from either the previously described *t*-butyl alcohol or PTC conditions. Sharpless et al. *Angew. Chemie Intl Ed.* **1996**, 35, 451.

The use of chiral ligands with sulfonamides provides enantioselectivity and has been observed to both accelerate and decelerate the rate of catalysis. The hydroxysulfonamide process is a stereoselective *cis* process. The presence of ligands also has a dramatic effect on the regioselectivity. In a study with no ligand present with methyl cinnamate, the two regioisomers were present in a 2:1 ratio. With the addition of ligand, the ratio was improved to 5:1 or greater. Another positive effect of the ligand was its ability to suppress formation of diol by-product. *Angew. Chemie Intl Ed.* **1996**, 35, 451.

Preferred ligands for use with sulfonamides have included the use of monovalent cinchona alkaloids or

- 5 -

the bivalent phthalazine based, commercially available (DHQ)<sub>2</sub>PHAL and (DHQD)<sub>2</sub>PHAL alkaloids. Sharpless et al. *Angew. Chemie Intl Ed.* **1996**, 35, 451.

5           Temperature conditions for the hydroxysulfonamide asymmetric aminohydroxylations have varied from 60 °C to 25 °C for reactions including sulfonamides, auxiliary salts, ligands, phase transfer catalysts and stoichiometric or catalytic osmium species, primarily in organic solvents with small amounts of water.

10          Recently, it has been shown that temperature can be lowered to 0 °C while running the reaction, to obtain product by filtration; many hydroxysulfonamides tend to be highly crystalline.

          Cleavage of the sulfonamides, to free

15          aminoalcohols, have been accomplished via standard deprotection conditions including dissolving metals (Na, NH<sub>3</sub>; Sharpless et al *J. Org. Chem* **1976**, 41, 177) and HBr, acetic acid and phenol (Fukuyama et al. *Tetrahedron Lett.* in press).

20          What is needed is an improved method for catalyzing the symmetric aminohydroxylation of olefins, wherein the improvement enhances the yields, enantiomeric efficiency, and the regio-selectivity while reducing material and labor costs.

25

Summary of the Invention:

          The invention is directed to an improved method for converting olefinic substrates to asymmetric β-hydroxysulfonamide products. The method of the

30          invention employs an asymmetric addition reaction

- 6 -

involving the asymmetric addition of a nitrogen source and a hydroxyl radical to the olefinic substrate. Enhanced yields, regioselectivity, and enantioselectivity may be achieved according to the method of the invention. The asymmetric addition reaction is carried out in a reaction solution which includes the olefinic substrate, an osmium catalyst, a chiral ligand for enantiomerically and regioselectively directing the asymmetric addition, and a nitrogen source. The olefinic substrate is present and soluble within the reaction solution in stoichiometric amounts. The osmium is present within the reaction solution in catalytic amounts. One aspect of the improvement is directed to the use of a sulfonamide as the nitrogen source for forming an asymmetric hydroxysulfonamide intermediate. Preferred sulfonamides include chloramine compounds. Preferred reaction solutions include co-solvent mixtures containing both an organic component and an aqueous compound. Preferred organic components include acetonitrile, tert-butanol, and n-propanol. In a preferred co-solute, each of the organic and aqueous components is approximately 50% on a volume basis. In a preferred mode, the asymmetric hydroxysulfonamide reaction occurs in the substantial absence of ancillary salts, including silver salts and mercury salts. After the hydroxysulfonamide intermediate is formed, the asymmetric hydroxylamine product may be obtained by deprotecting the asymmetric hydroxysulfonamide intermediate for forming the asymmetric hydroxylamine product.



- 7 -

Description of Figures

Figure 1 illustrates the synthesis of  $\alpha$ -hydroxy-  
 $\beta$ -sulfonamide compounds **2** and **ent-2**. The synthetic  
5 conditions are as follows:  $K_2OsO_2(OH)_4$ , 4%;  $(DHQ)_2$ -PHAL  
or  $(DHQD)_2$ -PHAL, 5%;  $TsNClNa \cdot 3H_2O$ , 3 eq.;  $CH_3CN/H_2O$  or  
 $t$ -BuOH/ $H_2O$ , v/v=1:1; Room temp., 3 h, 0.07 M in olefin.

Figure 2 illustrates the synthesis of  $\alpha$ -hydroxy-  
10  $\beta$ -sulfonamide compounds **2** in 1:1 v/v  $t$ BuOH/ $H_2O$  and  
represents a solution-to-solid catalytic AA using only  
2.5 mol% ligand and 2.0 mol% osmium catalyst. Product  
**2** crystallizes as it is formed, isolation includes only  
filtration of the crude mixture. The synthetic  
15 conditions are as follows: Methyl cinnamate **1**,  
 $K_2OsO_2(OH)_4$ , 2.0%;  $(DHQ)_2$ -PHAL, 2.5%;  $TsNClNa \cdot 3H_2O$ , 3.5  
eq.;  $t$ BuOH/ $H_2O$ , v/v=1:1; Room temp., 3 h, 0.07 M in  
olefin; 69% yield, 82% ee.

Figure 3 illustrates the removal of the sulfonamide and  
methyl ester protecting groups from substrate **2** to form  
intermediate **3** which is subsequently converted to the  
taxol side chain via amide formation (step iii). The  
synthetic conditions are as follows: (i) HBr-HOAc,  
20 phenol, 75 °C; (ii) Amberlite 120 resin; (iii)  $PhCOCl$ ,  
25 2N NaOH,  $H_2O$ .

Figure 4 tabulates a series of products formed from  
catalytic asymmetric aminohydroxylation in 1:1  
30  $CH_3CN/H_2O$  (procedure 1).

- 8 -

[a] All absolute configurations have been determined, see experimental procedure. [b] Numbers in parentheses are after recrystallizations from methanol (in some cases, it is the mother liquor which is enantioenriched when the racemate crystallizes preferentially - in the case of methylcinnamate only 2.5 mol% ligand and 2.0 mol% osmium catalyst were used, due to the preferential crystallization); the melting points and optical rotations (in 95% ethanol) are for the highest ee samples in the (DHQ)<sub>2</sub>-PHAL column of Table 1. [c] The ee's in this column are for the products which are enantiomeric to those in the "Product" column. [d] 4:3 CH<sub>3</sub>CN/H<sub>2</sub>O was used as the solvent.

Figure 5 illustrates a suggested mechanism and reactive species formed via the generation of the  $\alpha$ -hydroxy- $\beta$ -sulfonamide **9** from cyclohexene and K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub>, 4%; (DHQ)<sub>2</sub>-PHAL or (DHQD)<sub>2</sub>-PHAL, 5%; TsNClNa.3H<sub>2</sub>O and 1:1 solvent mix.

Figure 6 tabulates a series of products formed from catalytic asymmetric aminohydroxylation in 1:1 t-BuOH/H<sub>2</sub>O (procedure 2).

[a] In this case, one half of the olefin was added at the beginning of the reaction and the rest was added in portions over 45 min starting one hour later. [b] The minor enantiomer is completely removed by two triturations with ethyl acetate which leaves a 50% yield of enantiopure (S,S)-5.

- 9 -

Figure 7 illustrates the effects of changing conditions on the synthesis of  $\alpha$ -hydroxy- $\beta$ -sulfonamide compound 11. An electron withdrawing substituent on the phenyl ring of methylcinnamate via *p*-nitro-methylcinnamate, coupled with a 3 solvent mix (EtOH(5)/*n*-propanol(3)/H<sub>2</sub>O(5) and 5 hour reaction time, increases enantiomeric excess to 94%, regioselectivity to 31:1 and yield to 86%. The synthetic conditions are as follows: K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub>, 4%; (DHQ)<sub>2</sub>-PHAL or (DHQD)<sub>2</sub>-PHAL, 5%; TsNClNa.3H<sub>2</sub>O, 3 eq.; (EtOH(5)/*n*-propanol(3)/H<sub>2</sub>O(5); Room temp., 5 h, 0.07 M in olefin.

Figure 8 shows a series of cinnamate derivatives which illustrate the effects of changing conditions. An electron withdrawing substituent on the phenyl ring of methylcinnamate as *p*-methoxy 12, *p*-bromo 14, *p*-nitro 16, *p*-nitro 10, *o*-nitro 18, *m*-nitro 20, *o*-methyl 22, 2,5 dimethyl 24, or 2,5 dimethoxy 26, coupled with a solvent mix of CH<sub>3</sub>CN/H<sub>2</sub>O, *n*-propanol/H<sub>2</sub>O, *t*-BuOH/H<sub>2</sub>O, v/v=1:1 or (EtOH(5)/*n*-propanol(3)/H<sub>2</sub>O(5) provided the indicated enantiomeric excesses, regioselectivities and yields. The synthetic conditions were as follows: K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub>, 4%; (DHQ)<sub>2</sub>-PHAL or (DHQD)<sub>2</sub>-PHAL, 5%; TsNClNa.3H<sub>2</sub>O, 3 eq.; indicated solvent mix; room temp., 3 h, 0.07 M in olefin.

Figure 9 illustrates a general synthesis of *N*-chloro-*N*-sodio-*R*-sulfonamides **RSO<sub>2</sub>NClNa**, where *R* consists of one of the following groups: 4-Me-Ph-, 4-MeOPh, Me, Ph-CH<sub>2</sub>- , 4-NO<sub>2</sub>-Ph-, 2-NO<sub>2</sub>-Ph-, 2-Naphthyl, 1-Naphthyl,

- 10 -

Dansyl or derivatives selected from the following functional groups: acyclic or cyclic hydrocarbons, hydroxyl compounds, ethers, protected amines, carbonyl compounds, esters or carboxylic acids, n-alkyl, pyrans, pyrroles, various heterocycles including: pyrazines, pyrazoles, pyridazines, pyridines, pyrimidines, pyrrolizines, quinazolines, quionlines, thiophenes, silanes,  $\text{CH}_n\text{X}$  where  $\text{X}=\text{OR}_1$ , halogens, aromatic rings, heterocycles, silyl groups and  $n=1$  to  $2$ .

Figure 10 illustrates a general aminohydroxylation reaction (AA) for the olefin  $\text{R}_1\text{CHCHR}_2$  using *N*-chloro-*N*-sodio- $\text{R}_3$ -sulfonamides  $\text{R}_3\text{SO}_2\text{NClNa}$  and various reaction conditions including  $\text{K}_2\text{OsO}_2(\text{OH})_4$ , 2-4%;  $(\text{DHQ})_2\text{-PHAL}$  or  $(\text{DHQD})_2\text{-PHAL}$ , 2.5-5%;  $\text{TsNClNa} \cdot 3\text{H}_2\text{O}$ , 3-5 eq.; indicated solvent mixes including  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ , *n*-propanol/ $\text{H}_2\text{O}$ , *t*-BuOH/ $\text{H}_2\text{O}$ ,  $v/v=1:1$  or  $(\text{EtOH}(5)/\text{n-propanol}(3)/\text{H}_2\text{O}(5))$ ; room temp., 3-5 h, .01- 0.07 M in olefin.

$\text{R}_1$  = acyclic or cyclic hydrocarbons, heterocycles, hydroxyl compounds, ethers, protected amines, sulfides, carbonyl compounds, acrylates, substituted acrylates, esters or carboxylic acids.

$\text{R}_2$  = combination of  $\text{R}_1$

$\text{R}_3$  = 4-Me-Ph-, 4-MeOPh, Me, Ph-CH<sub>2</sub>- , 4-NO<sub>2</sub>-Ph-, 2-NO<sub>2</sub>-Ph-, 2-Naphthyl, 1-Naphthyl, Dansyl or derivatives selected from the following functional groups: acyclic or cyclic hydrocarbons, hydroxyl compounds, ethers, protected amines, carbonyl compounds, esters or carboxylic acids, n-alkyl, pyrans, pyrroles, various heterocycles including: pyrazines, pyrazoles, pyridazines, pyridines, pyrimidines, pyrrolizines,

- 11 -

quinazolines, quionlines, thiophenes, silanes,  $\text{CH}_n\text{X}$  where  $\text{X}=\text{OR}_1$ , halogens, aromatic rings, heterocycles, silyl groups and  $n=1$  to 2.

5 Figure 11 illustrates the catalytic asymmetric aminohydroxylation of isopropyl cinnamate by addition of *N*-chloro-*N*-sodio-R-sulfonamides or *in situ* generation of  $\text{R-SO}_2\text{NClNa}$  via  $\text{R-SO}_2\text{Cl}$ . R = 4-Me-Ph-, 4-MeOPh, Me, Ph-CH<sub>2</sub>- , 4-NO<sub>2</sub>-Ph-, 2-NO<sub>2</sub>-Ph, 2-Naphthyl, 1-Naphthyl, Dansyl or derivatives selected from the following functional groups: acyclic or cyclic hydrocarbons, hydroxyl compounds, ethers, protected amines, carbonyl compounds, esters or carboxylic acids, n-alkyl, pyrans, pyrroles, various heterocycles including: pyrazines, pyrazoles, pyridazines, pyridines, pyrimidines, pyrrolizines, quinazolines, quionlines, thiophenes, silanes,  $\text{CH}_n\text{X}$  where  $\text{X}=\text{OR}_1$ , halogens, aromatic rings, heterocycles, silyl groups and  $n=1$  to 2.

20 Figure 12 tabulates the catalytic asymmetric aminohydroxylation of isopropyl cinnamate by *in situ* generation of  $\text{R-SO}_2\text{NClNa}$  via  $\text{R-SO}_2\text{NH}_2$  to give compounds **28-47** with respective conditions indicated. R = 4-Me-Ph-, 4-MeOPh, Me, Ph-CH<sub>2</sub>- , 4-NO<sub>2</sub>-Ph-, 2-NO<sub>2</sub>-Ph, 2-Naphthyl, 1-Naphthyl, Dansyl or derivatives selected from the following functional groups: acyclic or cyclic hydrocarbons, hydroxyl compounds, ethers, protected amines, carbonyl compounds, esters or carboxylic acids, n-alkyl, pyrans, pyrroles, various heterocycles

- 12 -

including: pyrazines, pyrazoles, pyridazines,  
pyridines, pyrimidines, pyrrolizines, quinazolines,  
quionlines, thiophenes, silanes,  $\text{CH}_n\text{X}$  where  $\text{X}=\text{OR}_1$ ,  
halogens, aromatic rings, heterocycles, silyl groups  
and  $n=1$  to 2.

Figure 13 illustrates additional *N*-chloro-*N*-sodio-**R**-  
sulfonamides derivatives  $\text{R-SO}_2\text{NClNa}$  selected from the  
following functional groups: **R** = acyclic or cyclic  
hydrocarbons, hydroxyl compounds, ethers, protected  
amines, carbonyl compounds, esters or carboxylic acids,  
*n*-alkyl, alkynes (60) pyrans, pyrroles (54), various  
heterocycles including: nitriles (58), pyrazines,  
pyrazoles (55), pyridazines, pyridines (57), pyrimidines  
(59), pyrrolizines, quinazolines, quionlines,  
thiophenes, silanes,  $\text{CH}_n\text{X}$  where  $\text{X}=\text{OR}_1$ , halogens,  
aromatic rings, heterocycles, silyl groups and  $n=1$  to 2  
(56).

Figure 14 illustrates the AA (asymmetric  
aminohydroxylation) reaction of dimethylfumarate under  
conditions which utilize 3.0 equivalents of *N*-chloro-*N*-  
sodio-methanesulfonamide (Chloramine M) to achieve a  
98% ee (enantiomeric excess) and 62% overall yield of  
49.

Figure 15 tabulates the AA (asymmetric  
aminohydroxylation) for a series of substrates under  
conditions which utilize 3.0 equivalents of *N*-chloro-*N*-  
sodio-methanesulfonamide (Chloramine M). (1)

- 13 -

performing this reaction at 17 °C, the enantioselectivity was > 98%; (2) yields not optimized.

Figure 16 illustrates a series of products formed from the AA (asymmetric aminohydroxylation) of selected acrylates and methacrylates (entries 1-10). The synthetic conditions are as follows:  $K_2OsO_2(OH)_4$ , 4%; (DHQ)<sub>2</sub>-PHAL or (DHQD)<sub>2</sub>-PHAL, 5%;  $TsNClNa \cdot 3H_2O$  (chloramine T), 3 eq.;  $CH_3CN/H_2O$  or  $t-BuOH/H_2O$ , v/v=1:1; Room temp., 3 h, 0.07 M in olefin.

Figure 17 illustrates a series of products formed from the AA (asymmetric aminohydroxylation) of *t*-butyl acrylate. The synthetic conditions are as follows:  $K_2OsO_2(OH)_4$ , 4%; (DHQ)<sub>2</sub>-PHAL or (DHQD)<sub>2</sub>-PHAL, 5%;  $TsNClNa \cdot 3H_2O$  (chloramine T), 3 eq.;  $CH_3CN/H_2O$  or  $t-BuOH/H_2O$ , v/v=1:1; Room temp., 3 h, 0.07 M in olefin and indicated changes as noted with the respective enantiomeric excess (ee) listed

#### Detailed Description:

A synthetic method is disclosed herein for obtaining β-hydroxysulfonamides and β-hydroxyamines directly from olefins in enantiomerically enriched form. The new osmium-catalyzed asymmetric process is exemplified in Scheme 1 by the synthesis of the Taxol sidechain enantiomers (2 and **ent-2**) from methyl cinnamate (1). This catalytic aminohydroxylation (AA) is obviously a close relative of the catalytic asymmetric dihydroxylation (AD), see H. C. Kolb, et

- 14 -

al., Chem. Reviews 1994, 94, 2483. In fact, its stoichiometric analog was first reported in 1980 as a footnote in the initial report on the stoichiometric asymmetric dihydroxylation process, e.g., see note 22 in S. G. Hentges and K. B. Sharpless, J. Am. Chem. Soc. 1980, 102, 4263. Stoichiometric AA's have also been reported recently by H. Rubinstein and J.S. Svendsen, Acta Chem. Scand. 1994, 48, 439 and by C. Y. Park, Ph.D. thesis, Massachusetts Institute of Technology, Cambridge, MA, 1991. However, both the AD and the AA, being at first only stoichiometric reactions, were pushed aside by the titanium-catalyzed asymmetric epoxidation process (AE), also discovered in 1980. (T. Katsuki and K. B. Sharpless, J. Am. Chem. Soc. 1980, 102, 5974.) Ever since the discovery of the catalytic AD in 1987, we have tried to render the AA catalytic. (E. N. Jacobsen, et al., J. Am. Chem. Soc. 1988, 110, 1968.)


Initially, success was very limited. The first, albeit inefficient, asymmetric aminohydroxylations were performed by Christopher J. Burns and Declan Gilheanny in the Sharpless' laboratory at the Massachusetts Institute of Technology in 1987, unpublished results. It is disclosed herein how to run the reaction under conditions which allow the catalytic cycle to turnover at a useful rate. The process disclosed herein combines the AD's phthalazine ligands and the osmium-catalyzed aminohydroxylations. (See K. B. Sharpless, et al., Org. Chem. 1976, 41, 177; E. Herranz, et al., J. Org. Chem. 1978, 43, 2544; E. Herranz, et al., J. Am. Chem. Soc. 1978, 100, 3596; E. Herranz and K. B. Sharpless, J.



- 15 -

Org. Chem. 1980, 45, 2710; E. Herranz and K. B. Sharpless, Org. Synth. 1983, 61, 85; E. Herranz and K. B. Sharpless, Org. Synth. 1981, 61, 93; For Palladium-promoted aminohydroxylation (oxyamination) see: J. E. Bäckvall and E. E. Björkman, J. Org. Chem. 1980, 43, 2893; and J. E. Bäckvall, Tetrahedron Lett. 1975, 26, 2225.) Other than the asymmetric induction, the most dramatic effect of the alkaloid ligand is on the regioselectivity. In the original study (no ligand present) with methyl cinnamate (1) the C-3 sulfonamide isomer 2 and its regioisomer, with the sulfonamide substituent at C-2, were produced in a 2:1 ratio. In the present system this ratio is improved to 5:1 or greater. In fact, at the early stage (i.e. ~5% conversion) of the reaction with methyl cinnamate this ratio is > 20:1 and the enantiomeric purity of the major regioisomer (2) is about 95% ee. Both regioselectivity and enantioselectivity drop continuously as the reaction proceeds. This is tentatively attributed to intrusion of a "second cycle". Ethyl crotonate (entry 2, Table 1) benefits from this same ligand effect. Another positive effect of the ligand is its ability to suppress formation of the diol by-product, which in the absence of the ligand is substantial in this new system.

- 16 -



Scheme 1:  $\text{K}_2 \text{OsO}_2(\text{OH})_4$ , 4%;  $(\text{DHQ})_2\text{-PHAL}$  or  $(\text{DHQD})_2\text{-PHAL}$ , 5%;  $\text{TsNClNa}\cdot 3\text{H}_2\text{O}$ , 3 eq.;  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$  or  $t\text{-BuOH}/\text{H}_2\text{O}$ , v/v=1:1; Room temp., 3 h, 0.07 M in olefin.

**Legend for Table 1:**

Catalytic asymmetric aminohydroxylation in 1:1  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$  (procedure 1). [a] All absolute configurations have been determined, see experimental procedure. [b] Numbers in parentheses are after recrystallizations from methanol (in some cases, it is the mother liquor which is enantioenriched when the racemate crystallizes preferentially); the melting points and optical rotations (in 95% ethanol) are for the highest ee samples in the  $(\text{DHQ})_2\text{-PHAL}$  column of Table 1. [c] The ee's in this column are for the

- 17 -

products which are enantiomeric to those in the "Product" column. [d] 4:3 CH<sub>3</sub>CN/H<sub>2</sub>O was used as the solvent.

Table 1 reveals that the process in its present form yields only modest enantioselectivities (33-81%). On the other hand, the first report on the catalytic AD did not look much better (20-88% ee) [1a] and this new process offers considerably more variables for optimization efforts. Even the present results are useful since hydroxysulfonamides tend to be highly crystalline, and can usually be raised to enatiopurity by recrystallization. This is the case for the Taxol side-chain derivative 2, which following deprotection by treatment with 33% HBr in acetic acid for 10 hours at 75 °C gives the enantiopure n -hydroxy-β-amino acid in 70% yield. While the core functionality of toluenesulfonamide derivative 2 survives these strongly acidic conditions, many molecules would not. Indeed, the notorious problems associated with deprotection of sulfonamides are a serious concern for this AA process. Fortunately, there has been a breakthrough from the Fukuyama group (T. Fukuyama, et al., Tetrahedron Lett.

- 18 -

1995, 36, 6376.), which promises to make sulfonamide protection for nitrogen extremely popular. In any case, the vigorously acidic, yet successful conditions for deprotection of the Taxol side-chain precursor

5. (vide supra) reveal that more molecules than previously imagined may tolerate the old brute-force approach for hydrolysis of aromatic sulfonamides.

- 19 -


Synthetic Protocols

**General experimental.** All reagents and solvents were purchased from commercial sources and used as received unless stated otherwise. All commercial chemicals were used without purification and their stoichiometries were calculated based on the reported purities from the manufacturer. (DHQD)<sub>2</sub>PHAL, 95% (hydroquinidine 1,4-phthalazinediyl diether), (DHQ)<sub>2</sub>PHAL, 97% (hydroquinine 1,4-phthalazinediyl diether), chloramine-T-hydrate 98% (N-chloro-p-toluenesulfonamide, sodium salt) are commercially available from Aldrich Chemical Company. Additionally, the (DHQ)<sub>2</sub> and (DHQD)<sub>2</sub> ligands can be prepared from the procedure of Sharpless et al. *J. Org. Chem.* **1992**, 57, 2768. Melting points were measured without correction with a Thomas-Hoover capillary apparatus. Optical rotations were recorded on an Autopol III polarimeter (Rudolph Research, Fairfield, N. J.). <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker AMX 400 instrument. Stoichiometries are calculated based on the purities reported by the manufacturer (trans-stilbene: 96%; Chloramine-T trihydrate: 98%).

- 20 -

The  $K_2OsO_2(OH)_4$  should be mauve rather than brown/black and should be dry for the best yields and ee's (the hygroscopic nature of the salt affects the amount of osmium dispensed). All new compounds gave satisfactory spectroscopic analyses ( $^1H$ -NMR, IR, HRMS). Enantiomeric excesses (ee's) were determined by HPLC using Chiracel columns (Daicel Chemical Industries) and isopropanol/hexane (v/v) mobile phases; the retention time of the major enantiomer from the  $(DHQ)_2$ -PHAL reaction is in italics. The vicinal hydroxysulfonamides derived from AA reactions using  $(DHQ)_2$ -PHAL as the chiral ligand were correlated to compounds of known absolute configuration by HPLC.

**Synthesis of (2R,3S)-(+)-Methyl-N-(p-toluenesulfonyl)-2-hydroxy-3-amino-3-phenyl-propionate (2) in t-BuOH (figures 1 and 2):**



**Compound 2.** To a 2 L round-bottom flask, equipped with

- 21 -

a mechanical stirrer and a thermometer, was added (DHQ)-PHAL (6.6 g, 2.5 mol%), *t*-BuOH (600 mL) and H<sub>2</sub>O (600 mL). The flask was immersed in a room temperature water bath. To the resulting homogeneous solution was added in order 290.4 g (1.01 mol) of Chloramine-T trihydrate (ca. 4/5 of the total added which is in 338 g, 1.18 mol), methyl cinnamate (27.2 g, 167.6 mmol, half of the total amount of olefin, which is 54.4 g, 0.33 mol; Aldrich chemical company) and potassium osmate(VI; Aldrich) (2.5 g, 2.0 mol%). As the reaction was stirred, the color changed from yellow to green in 15 min and then back to yellow after 90 min; TLC(EtOAc/Hexane, v/v = 4/6) revealed that the disappearance of olefin coincided with the return of the yellow color. The flask was then immersed in an ice bath (0 °C) for 20 min. (During this cooling, the crystals of precipitated product made their first appearance.) To this cold, stirred suspension the remainder of the Chloramine-T trihydrate (48.4 g, 0.168 mol) and the second portion of methyl cinnamate (13.6 g, 84 mmol) was added. The ice bath was replaced by the room temperature water bath, and the new olefin charge

- 22 -

was consumed in about 45 min during which time the color changed as before from yellow to green and back to yellow again. The resulting mixture was cooled back to 0 °C for over 15 min and the third and last portion  
5 of methyl cinnamate (13.6 g, 84 mmol) was added. The reaction was returned to the room-temperature water bath and the remaining olefin was consumed in about 45 min with the above noted sequence of color changes. The flask was again immersed in an ice bath (0 °C) for  
10 about 20 min. Essentially all of the product precipitated out of solution and was isolated by filtration, washed twice with cold (ca 0 °C) 100 mL portions of t-BuOH/H<sub>2</sub>O (v/v = 1/1) to yield 81.1 g of  
(2R,3S)-(+)-methyl-N-(p-toluenesulfonyl)-2-hydroxy-3-amino-3-phenyl propionate (2) (69% yield, 82% ee, m.p.  
15 147-148 °C; for racemic: m.p. 125-126 °C 4c).


A 6.3 g portion of this crude 2 was triturated with EtOAc at room temperature (1 x 75 mL, 1 x 35 mL and 2 x 20 mL), the solid triturand of 2 remaining  
20 after these triturations is of low ee and is discarded. Concentration of the combined triturates afforded 5.3 g of enantiomerically enriched 2 (58 % yield, 92% ee),



- 23 -

three recrystallizations from MeOH gave 3.2 g of enantiomerically pure product 2 (35% yield based on 1), m.p. 154-155 °C;  $[\alpha]_D^{25} = +19.8^\circ$  (c 0.5, 95% EtOH);  $^1\text{H}$  NMR (400 MHz, DMSO/ $\text{D}_2\text{O}$ )  $\delta$  2.23 (s, 3H), 3.45 (s, 3H), 4.17 (d,  $J = 4.0$  Hz, 1H), 4.65 (d,  $J = 4.0$  Hz, 1H), 7.08-7.19 (m, 8H), 7.40 (d,  $J = 8.2$  Hz, 2H);  $^{13}\text{C}$  NMR (100 MHz, DMSO)  $\delta$  171.8, 141.9, 138.4, 138.7, 128.9, 127.6, 127.3, 126.9, 126.4, 74.4, 60.1, 51.6, 20.9.

**Synthesis of (2R,3S)-(+)-Methyl-N-(p-toluenesulfonyl)-2-hydroxy-3-amino-3-phenyl-propionate (2) in n-Propanol:**




81.1 g, m.p. 147-148 °C  
(69% yield, 82% ec)

To a solution of (DHQ)<sub>2</sub>-PHAL (2.20 g, 2.80 mmol, 5 mol%) in n-Propanol (100 mL) and water (100 mL) in 500 mL Erlenmeyer or round-bottomed flask were added in order, methyl cinnamate (9.08 g, 56.0 mmol),

- 24 -

Chloramine-T trihydrate (48.4 g, 0.168 mol, 3.0 eq) and  
K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> (0.824 g, 2.24 mmol, 4 mol%). The reaction  
flask was immersed in a room-temperature water bath and  
the slurry stirred for 3 hr. Over the course of the  
5 reaction, the color changed from brown to deep green  
and then back to yellow as hydroxysulfonamide product  
appeared as white precipitates. The flask was then  
immersed in an ice bath (0 °C) for 20 min. During this  
cooling, almost all of crystalline hydroxysulfonamide  
10 product precipitated from the reaction solution. The  
product was isolated by filtration and the crude solid  
was washed once with cold (ca 5 °C) 1:1 n-  
Propanol/H<sub>2</sub>O (15 mL) to yield 11.7 g of (2R,3S)-(+)-  
methyl-N-(p-toluenesulfonyl)-2-hydroxy-3-amino-3-phenyl  
15 propionate (60% yield, 89% ee).

**Synthesis of (2R,3S)-2-hydroxy-3-amino-3-phenylpropionic acid (3); (figure 3)**



**3**  
77%


- 25 -

**Compound 3.** A heavy-walled borosilicate pressure bottle was charged with the enantiomerically enriched (92% ee) 2 [i.e. the triturated but not recrystallized material (vide supra)] (1.25 g, 3.6 mmol), phenol (1.04 g, 11.1 mmol) and excess 33% hydrogen bromide in acetic acid (20 mL, 0.117 mol, Acros). The bottle was sealed with a bushing, having a Teflon-lined cap, before being immersed completely in an oil bath. The bath was maintained at 75 °C for 10-12 h. The resulting solution was then concentrated in vacuo to about 10 mL (water pump followed by an oil pump which was protected by a 0 °C aqueous KOH bubbler). The crude solution was purified by ion-exchange chromatography (Amberlite IR-120 resin, 35 g), eluting with 80 mL of water (to remove impurities), then with 80 mL of 10% ammonium hydroxide (start with a dilute solution due the heat generated in the ion exchange process) followed by 80 mL of 40% ammonium hydroxide. Collection of the ammonium hydroxide eluate gave a solution of the ammonium salt of 3 which upon lyophilization yielded pure (2R,3S)-2-hydroxy-3-amino-3-phenylpropionic acid

- 26 -

(37, 0.51 g, 77%). m.p. 235 °C, decomp. (literature: Deng et. al J. Org. Chem. 57, (1992), 4320: m.p. 238 °C, decomp.); rotation after conversion to the hydrochloride salt is  $[\alpha]_D^{25} = -14.5^\circ$  (c 0.37, MeOH;  $[\alpha]_D^{25} -15.1^\circ$  c 0.365, MeOH). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O)  $\delta$  4.09 (d, J = 6.0 Hz, 1H), 4.32 (d, J = 6.0 Hz, 1H), 7.21-7.41 (m, 5H); <sup>13</sup>C NMR (100 MHz, D<sub>2</sub>O/DMSO)  $\delta$  177.7, 135.4, 130.9, 130.7, 128.9, 75.0, 59.0.

**N-Benzoyl-(2R,3S)-2-hydroxy-3-amino-3-phenylpropionic Acid (4); figure 3.**



**4**  
65%

**Compound 4.** The enantiomerically enriched 37 (0.43 g, 2.37 mmol) was converted to N-benzoyl-(2R,3S)-2-hydroxy-3-amino-3-phenylpropionic acid (4, 0.44 g, 65%) according to our earlier Schotten-Baumann-based procedure for this same transformation (Sharpless et

- 27 -

al. J. Org. Chem. 59 (1994), 5104). Chemically and enantiomerically pure 4 was isolated by simple filtration of the solid which appeared when the pH of the reaction mixture was adjusted to ca. 2 by addition of aqueous HCl. m.p. 166-167 °C (lit: Ojima et al. J. Org. Chem 56 (1991) 1681: 167-169 °C); [a]<sub>D</sub><sup>25</sup> -34.0° (c 0.50, EtOH) (lit: Sharpless et al. J. Org. Chem. 1976, 41, 177: [a]<sub>D</sub><sup>25</sup> -35.9° c 0.565, EtOH); lit<sub>3d</sub> [a]<sub>D</sub><sup>25</sup> -35.5° (c 1.07, EtOH); <sup>1</sup>H NMR (400 MHz, DMSO) δ 4.37 (d, J = 4.3 Hz, 1H), 5.46 (dd, J = 8.8, 4.2 Hz, 1H), 7.22-7.55 (m, 9H), 7.84 (d, J = 7.2 Hz, 1H), 8.60 (d, J = 8.9 Hz, 1H), 12.73 (br, 1H); <sup>13</sup>C NMR (100 MHz, DMSO) δ 173.5, 166.0, 140.3, 134.4, 131.4, 128.4, 128.0, 127.4, 127.2, 126.9, 73.6, 55.8.

15

**General procedure 1 (Figure 4): Catalytic asymmetric aminohydroxylation in 1:1 acetonitrile/water (used for synthesis of compounds 2, 5, 6, 7, 8 or 9).** To a stirred solution of (DHQ)<sub>2</sub>-PHAL (0.11 g, 0.14 mmol, 5 mol%) in 20 mL of acetonitrile and 20 mL of water, in any convenient-sized glass vessel or vial, was added desired olefin (all commercially available from

20

- 28 -

Aldrich, **figure 4**, 2.8 mmol), Chloramine-T trihydrate (2.42 g, 8.4 mmol, 3 eq) and  $K_2OsO_2(OH)_4$  (41.6 mg, 0.112 mmol, 4 mol%). As the reaction proceeded to completion over the course of about one and half hours at room temperature, the color of the solution changed from yellow to pale green, then deep green and finally back to yellow (for entry 3 in Table 1, the yellow color remains throughout). After addition of aqueous sodium sulfite (1.0 g in 15 mL  $H_2O$ ), the phases were separated, and the aqueous phase extracted with ethyl acetate (3x15 mL). The combined organic extracts were washed with brine, dried over  $MgSO_4$  and the solvent concentrated to give the crude product, which also contains the p-toluenesulfonamide by-product produced upon the reduction of the excess Chloramine-T. In the case of the ethyl crotonate derivative, product 5, flash chromatography (6:4:1 hexane/ $CHCl_3$ /MeOH) of this material provided 0.44 g (52% yield, 74% ee) of (2R,3S)-ethyl-N-(p-toluenesulfonyl)-2-hydroxy-3-amino-butanoate (5) as a clear oil eluting before the p-toluenesulfonamide impurity (52% yield, 74 % ee). Similar purification provides compounds 2, 6, 7, 8 and

- 29 -

9. with the indicated yields and conditions shown in figure 4.

NOTE: Replacement of the 3 eq of Chloramine-T with 1.5 eq of Chloramine-T and 1.5 eq of Et<sub>4</sub>NOAc gives

comparable results and reduces the amount of p-toluenesulfonamide by-product formed. This can greatly simplify product isolation, especially in cases where the product and the toluenesulfonamide have similar chromatographic mobilities.

**General Procedure 2 (Figure 6): Catalytic asymmetric aminohydroxylation in 1:1 tertbutanol/water (used for synthesis of compounds 2, 7 or 8).** To a solution of (DHQ)2-PHAL (2.20 g, 2.80 mmol, 5 mol%) in t-BuOH (100 mL) and water (100 ml) in 500 mL Erlenmeyer or round-bottomed flask were added in order, desired olefin (56.0 mmol), Chloramine-T trihydrate (48.4 g, 0.168 mol, 3.0 eq) and K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> (0.824 g, 2.24 mmol, 4 mol%). The reaction flask was immersed in a room-temperature water bath and the slurry stirred for 2.5 hr. Over the course of the reaction, the color changed from brown to deep green and then back to yellow as the

- 30 -

stilbene slurry became a hydroxysulfonamide slurry. The product was isolated by filtration and the crude solid was washed once with cold (ca 5 °C) 1:1 t-BuOH/H<sub>2</sub>O (15 mL) to yield the product  $\beta$ -hydroxysulfonamide. In the case of product 7, 16.1 g of N-(p-toluenesulfonyl)-(1S,2S)-2-amino-1,2-diphenylethanol (7) (78% yield, 64% ee, pure by NMR and HPLC). Trituration of this product twice with ethyl acetate (2x15 mL) at room temperature in a sintered glass funnel gave enantiomerically pure 7 (10.3 g, 50% yield, > 99% ee, mp 166-167 °C). See Sharpless, J. Org. Chem. 1994, 59, 5104 and Sharpless, J. Org. Chem. 1994, 59, 8302 for analogous solid-to-solid AD procedures.

**Analysis of enantiomeric excesses for 2-9.** Methyl cinnamate derivative 2: Chiralcel OG, 30% i-PrOH/hexane, 1 mL/min; 21.8 min (2S,3R), 28.3 min (2R,3S). Ethyl crotonate derivative 5: Chiralcel OD-H, 15% i-PrOH/hexane, 1 mL/min, 7.5 min (2S,3R), 13.4 min (2R,3S). Dimethyl fumarate derivative 6: Chiralcel OG, 30% i-PrOH/hexane, 1 mL/min, 16.7 min (2S,3S), 21.8 min (2R,3R). trans-Stilbene derivative 5: Chiralcel OD-H,




- 31 -

15% i-PrOH/hexane, 1 mL/min, 16.2 min (1S,2S), 26.0 min  
(1R,2R). cis-Stilbene derivative **8**: Chiralcel OD-H, 15%  
i-PrOH/hexane, 0.5 mL/min, 18.5 min (1S,2R), 22.1 min  
(1R,2S). Cyclohexene derivative **9**: Chiralcel OG, 15% i-  
5 PrOH/hexane, 0.5 mL/min, 28.5 min (1S,2R), 34.4 min  
(1R,2S).

**Correlation of the absolute configurations of 2-9.**


**Methyl cinnamate derivative (2R,3S)-2:** Authentic  
10 (2R,3S)-2 was synthesized from N-benzoyl-(2R,3S)-3-  
phenylisoserine methyl ester (Taxol C-13 side chain;  
synthesis provided from Collet et al, Ecole normal  
superiure de Lyon, private communication) [6N HCl,  
reflux (remove methyl ester and N-benzoyl); SOCl<sub>2</sub>,  
15 methanol (esterification); TsCl, K<sub>2</sub>CO<sub>3</sub>, 1:1  
acetone/water (N-sulfonylation)] [HPLC: vide supra].

**Ethyl crotonate derivative (2R,3S)-5:**

5

**Compound 5:** (2R,3S)-5 was converted to N-tosyl-(2S)-alanine methyl ester [6N HCl (hydrolysis); RuCl<sub>3</sub>/H<sub>5</sub>IO<sub>6</sub> (oxidative cleavage); SOCl<sub>2</sub>, methanol (esterification)] [HPLC: Chiralcel OD-H, 15% i-PrOH/hexane, 1 mL/min, 16.1 min (2R), 17.0 min (2S)].

10

**Dimethyl fumarate derivative (2R,3R)-6:**

15


**Compound 6:** (2R,3R)-6 was converted to its N-tosyl-(2R,3R)-2-oxazolidinone derivative which was independently synthesized from (1S,2S)-7 [carbonyl diimidazole, CH<sub>2</sub>Cl<sub>2</sub>; RuCl<sub>3</sub>, H<sub>5</sub>IO<sub>6</sub> (oxidative degradation of the phenyl groups); (Polt et. al. *J. Org. Chem.* **1992**, 57, 5469), SOCl<sub>2</sub>, methanol (esterification)] [HPLC:

20

- 33 -


Chiralcel OD-H, 15% i-PrOH/hexane, 1 mL/min, 26.0 min  
(1R,2R), 47.2 min (1S,2S)].

**trans-Stilbene derivative (1S,2S)-7:**




**Compound 7:** An authentic sample of (1S,2S)-7 was  
synthesized from (1R,2S)-8 [CrO<sub>3</sub>, H<sub>2</sub>SO<sub>4</sub> (alcohol to  
10 ketone); DIBAL-H reduction gave a 4:1 mixture of  
(1R,2S)-8 to (1S,2S)-7] [HPLC: vide supra].

**cis-Stilbene derivative (1S,2R)-8:**



**Compound 8:** An authentic sample of (1R,2S)-8 was  
synthesized from (1R,2S)-2-amino-1,2-diphenylethanol  
[TsCl, K<sub>2</sub>CO<sub>3</sub>, acetone/water] [HPLC: vide supra].

20 **Cyclohexene derivative (1S,2R)-9:**



- 34 -

**Compound 9:** N,N'-ditosyl-(1R,2R)-diaminocyclohexane was synthesized from (1S,2R)-7 [SO<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, EtOAc; NaH (cyclic sulfamidate formation); NaN<sub>3</sub> (opening); H<sub>2</sub>, Pd/C (azide reduction); TsCl, K<sub>2</sub>CO<sub>3</sub>, 1:1 acetone/water] and compared to the compound derived from authentic (1R,2R)-diaminocyclohexane [22] [HPLC: Chiralcel AS, 20% i-PrOH/hexane, 1 mL/min, 23.2 min (1R,2R), 32.3 min (1S,2S)].

**Catalytic asymmetric aminohydroxylation in 1:1**


**tertbutanol/water (used for synthesis of compounds 2, 13, 15, 23, 25 or 27) as illustrated in FIGURE 8:**

**Compounds 2, 13, 15, 23, 25 or 27.** To a solution of (DHQ)<sub>2</sub>-PHAL (2.20 g, 2.80 mmol, 5 mol%) in t-BuOH (100 mL) and water (100 mL) in 500 mL Erlenmeyer or round-bottomed flask were added in order, desired olefin (methyl cinnamate, p-methoxy-methyl-cinnamate **12**, p-bromo-ethyl-cinnamate **14**, o-methyl-methyl-cinnamate **22**, 2,5-dimethyl-methyl-cinnamate **24** or 2,5-dimethoxy-methyl-cinnamate **26**; all commercially available from Aldrich) (56.0 mmol), Chloramine-T trihydrate (48.4 g,

- 35 -

0.168 mol, 3.0 eq) and  $K_2OsO_2(OH)_4$  (0.824 g, 2.24 mmol, 4 mol%). The reaction flask was immersed in a room-temperature water bath and the slurry stirred for 2.5 hr. Over the course of the reaction, the color changed from brown to deep green and then back to yellow as the stilbene slurry became a hydroxysulfonamide slurry. The product was isolated by filtration and the crude solid was washed once with cold (ca 5 °C) 1:1 t-BuOH/H<sub>2</sub>O (15 mL) to yield the product  $\beta$ -hydroxysulfonamide. Trituration of this product twice with ethyl acetate (2x15 mL) at room temperature in a sintered glass funnel gave enantiomerically pure  $\beta$ -hydroxysulfonamide compounds **2**, **13**, **15**, **23**, **25** or **27**.

Catalytic asymmetric aminohydroxylation in 1:1:1 ethanol/n-propanol/water (used for synthesis of compound **11**) as illustrated in FIGURES 7 and 8.



**11**: 94%ee  
Regioselectivity: 31:1  
Yield: 86%

- 36 -

To a solution of (DHQ)<sub>2</sub>-PHAL (2.20 g, 2.80 mmol, 5 mol%) in ethanol (63 mL) n-Propanol (63 mL) and water (63 mL) in 500 mL Erlenmeyer or round-bottomed flask were added in order, commercially available p-nitro methyl cinnamate derivative (**10**; Aldrich chemical company) (9.08 g, 56.0 mmol), Chloramine-T trihydrate (48.4 g, 0.168 mol, 3.0 eq) and K<sub>2</sub>O<sub>5</sub>O<sub>2</sub>(OH)<sub>4</sub> (0.824 g, 2.24 mmol, 4 mol%). The reaction flask was immersed in a room-temperature water bath and the slurry stirred for 5 hr. Over the course of the reaction, the color changed from brown to deep green and then back to yellow as hydroxysulfonamide product appeared as white precipitates. The flask was then immersed in an ice bath (0 °C) for 20 min. During this cooling, almost all of crystalline hydroxysulfonamide product precipitated from the reaction solution. The product was isolated by filtration and the crude solid was washed once with cold (ca 5 °C) 1:1 n-Propanol/H<sub>2</sub>O (15 mL) to yield enantiomerically pure β-hydroxysulfonamide compound **11** in 86% overall yield and 94% ee.

**Catalytic asymmetric aminohydroxylation in 1:1 n-**

- 37 -

propanol/water (used for synthesis of compounds 17, 19, 21, 23 or 25) as illustrated in FIGURE 8.

**Compounds 17, 19, 21, 23 or 25.** To a solution of

(DHQ)<sub>2</sub>-PHAL (2.20 g, 2.80 mmol, 5 mol%) in n-Propanol

(100 mL) and water (100 ml) in 500 mL Erlenmeyer or round-bottomed flask were added in order, commercially available methyl or ethyl cinnamate derivatives (**16**,

**18, 20, 22 or 24**; Aldrich chemical company) (9.08 g, 56.0 mmol), Chloramine-T trihydrate (48.4 g, 0.168 mol, 3.0 eq) and K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> (0.824 g, 2.24 mmol, 4 mol%).

The reaction flask was immersed in a room-temperature water bath and the slurry stirred for 3 hr. Over the course of the reaction, the color changed from brown to deep green and then back to yellow as


hydroxysulfonamide product appeared as white precipitates. The flask was then immersed in an ice bath (0 °C) for 20 min. During this cooling, almost all of crystalline hydroxysulfonamide product

precipitated from the reaction solution. The product

was isolated by filtration and the crude solid was washed once with cold (ca 5 °C) 1:1 n-Propanol/H<sub>2</sub>O (15 mL) to yield enantiomerically pure β-hydroxysulfonamide

compounds 17, 19, 21, 23 or 25.

**Preparation of sulfonamides from sulfonylchlorides (as illustrated in figure 9 and 13)**



The sulfonyl chlorides used in the formation of the sulfonamides can come from commercially available sources such as Aldrich, Fluka, Sigma etc., or can be prepared from a procedure developed by Campbell et al. *Chem Rev.* **1978**, 78, 65, for the preparation of N-chloro-N-sodiocarbamates which is a general procedure in the synthesis of N-chloro-N-sodio-aryl-and alkylsulfonamides. The sulfonyl chlorides ( $\text{R}-\text{SO}_2\text{Cl}$ ) formed can include compounds where  $\text{R} = 4\text{-Me-Ph-}$ ,  $4\text{-MeOPh-}$ ,  $\text{Me-}$ ,  $\text{Ph-CH}_2\text{-}$ ,  $4\text{-NO}_2\text{-Ph-}$ ,  $2\text{-NO}_2\text{-Ph-}$ ,  $2\text{-Naphthyl-}$ ,  $1\text{-Naphthyl-}$ , Dansyl (**figure 9 and 12**) or derivatives selected from the following functional groups: acyclic or cyclic hydrocarbons, hydroxyl compounds, ethers, protected amines, carbonyl compounds, esters or carboxylic acids, n-alkyl, alkynes (**60**) pyrans, pyrroles (**54**), various heterocycles including: nitriles (**58**), pyrazines,



- 39 -

pyrazoles (55), pyridazines, pyridines (57), pyrimidines (59), pyrrolizines, quinazolines, quionlines, thiophenes, silanes,  $\text{CH}_n\text{X}$  where  $\text{X}=\text{OR}_1$ , halogens, aromatic rings, heterocycles, silyl groups and  $n=1$  to 2 (56) (figure 13).

**Method A: using a sulfonyl chloride (as obtained supra) and gaseous  $\text{NH}_3(\text{g})$  (figure 9)**

$\text{NH}_3$  was bubbled (fritte or pipette) through well stirred  $\text{CH}_2\text{Cl}_2$  (ca 100 ml) at RT. The sulfonyl chloride (100 mmol) was added in portions. After all of the sulfonyl chloride was added, stirring at RT under  $\text{NH}_3$  was continued until TLC [hexane/ethylacetate] showed full conversion of the starting material. Precipitated  $\text{NH}_4\text{Cl}$  was filtered off, the solvent was evaporated ( $\text{NH}_3$ ) and the residue was crystallized from hot acetone / water and dried at high vacuum (oil pump, 0.1 - 0.01 torr) overnight to yield the crystalline, pure sulfonamides in nearly quantitative yields.

**Method B: using a sulfonyl chloride (as obtained supra) and aqueous ammonia (figure 9)**

- 40 -

The sulfonylchloride (100 mmol) was added portionwise to a well stirred aqueous solution (100 ml) of NH<sub>3</sub> (29.7 %. Fisher) at RT. After all of the sulfonyl chloride was added, stirring at RT was continued for 2  
5 more hours. The reaction mixture was slowly (NH<sub>3</sub>!) heated to reflux and then cooled down to ca 4 C. The precipitated product was filtered off and crystallized from hot acetone / water and dried at high vacuum (oil pump, 0.1 - 0.01 torr) overnight to yield the  
10 crystalline, pure sulfonamides in nearly quantitative yields.


Trimethylsilylethyl sulfonamide and related alkylsilyl-sulfonamides can be prepared according to a literature  
15 procedure: Steven M. Weinreb et al. Tetrahedron Lett. 1986, 27, 2099-2102.

**General catalytic asymmetric aminohydroxylation by in situ generation of chloramines different from**

20 **Chloramine T**

(in situ generation of R-SO<sub>2</sub>NClNa) as illustrated in figure 10.

- 41 -



- 5      **General procedure:** T-butyl hypochlorite was slowly added to a well stirred solution of the desired sulfonamide (as obtained *vide supra*; 3.1 mmol, 3.1 eq) and 122 mg (3.05 mmol, 3.05 eq) of NaOH in 7.5 ml of water at room temperature. After 10 more minutes of
- 10      stirring this solution was added dropwise to a solution of 40 mg (0.05 mmol, 0.05 eq) of (DHQ)<sub>2</sub>Phal or (DHQD)<sub>2</sub>Phal in 7.5 ml of MeCN (alternatively, a 1:1 mix of t-BuOH/water, n-propanol/water or 1:1:1 ethanol/n-proanol/water can be used, depending upon optimization
- 15      conditions). Subsequently 190 mg (1.0 mmol, 1.0 eq) of olefin where **R<sub>1</sub>** = acyclic or cyclic hydrocarbons, heterocycles, hydroxyl compounds, ethers, protected amines, sulfides, carbonyl compounds, acrylates, substituted acrylates, esters or carboxylic acids.
- 20      **R<sub>2</sub>** = combination of **R<sub>1</sub>**
- R<sub>3</sub>** = 4-Me-Ph-, 4-MeOPh, Me, Ph-CH<sub>2</sub>- , 4-NO<sub>2</sub>-Ph-, 2-NO<sub>2</sub>-Ph-, 2-Naphthyl, 1-Naphthyl, Dansyl or derivatives


- 42 -

selected from the following functional groups: acyclic or cyclic hydrocarbons, hydroxyl compounds, ethers, protected amines, carbonyl compounds, esters or carboxylic acids, n-alkyl, pyrans, pyrroles, various heterocycles including: pyrazines, pyrazoles, pyridazines, pyridines, pyrimidines, pyrrolizines, quinazolines, quionlines, thiophenes, silanes,  $\text{CH}_n\text{X}$  where  $\text{X}=\text{OR}_1$ , halogens, aromatic rings, heterocycles, silyl groups and  $n=1$  to  $2$  (reagents commercially or synthetically available) and  $14.7 \text{ mg}$  ( $0.04 \text{ mmol}$ ,  $0.04 \text{ eq}$ ) of  $\text{K}_2\text{OsO}_2(\text{OH})_4$  were added and the reaction mixture stirred at RT. After ca.  $10 \text{ min}$  all of the  $\text{K}_2\text{OsO}_2(\text{OH})_4$  was dissolved and the color of the reaction mixture turned to green. Stirring was continued until the green color of the reaction mixture had turned to yellow.  $10 \text{ ml}$  of aqueous  $\text{Na}_2\text{SO}_3$  (sat.) were added to reduce excess Chloramine. The aqueous phase was separated and extracted three times with ca.  $30 \text{ ml}$  ethyl acetate. The combined organic phases were washed with brine containing  $1 \%$  of  $\text{NaOH}$ , dried over  $\text{MgSO}_4$  (anhydrous) and the solvent was evaporated in vacu. The residue was purified by flash chromatography ( $\text{SiO}_2$ ,

- 43 -

hexane/ethyl acetate) to afford the pure crystalline aminohydroxylation product. In cases where regioisomeric products could be formed yields refer to a mixture of the two regioisomeres. Crystallization from ethyl acetate/ hexane furnished the enantiomerically pure (>99 %ee) N-aryl/alkylsulfonyl protected amino alcohol (**figure 10**)

**Catalytic asymmetric aminohydroxylation of compounds 28-47 by in situ generation of chloramines different from Chloramine T**  
(1 mmol scale, in situ generation of R-SO<sub>2</sub>NClNa) as illustrated in figure 11 and tabulated in figure 12.



20 **General procedure:** T-butyl hypochlorite was slowly added to a well stirred solution of the desired sulfonamide (as obtained *vide supra*; 3.1 mmol, 3.1 eq)

- 44 -

and 122 mg (3.05 mmol, 3.05 eq) of NaOH in 7.5 ml of water at room temperature. After 10 more minutes of stirring this solution was added dropwise to a solution of 40 mg (0.05 mmol, 0.05 eq) of (DHQ)<sub>2</sub>Phal or

5 (DHQD)<sub>2</sub>Phal in 7.5 ml of MeCN (alternatively, a 1:1 mix of t-BuOH/water, n-propanol/water or 1:1:1 ethanol/n-propanol/water can be used, depending upon optimization conditions). Subsequently 190 mg (1.0 mmol, 1.0 eq) of isopropyl cinnamate (commercially available from

10 Aldrich) and 14.7 mg (0.04 mmol, 0.04 eq) of K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> were added and the reaction mixture stirred at RT. After ca. 10 min all of the K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> was dissolved and the color of the reaction mixture turned to green. Stirring was continued until the green color of the

15 reaction mixture had turned to yellow.


10 ml of aqueous Na<sub>2</sub>SO<sub>3</sub> (sat.) were added to reduce excess Chloramine. The aqueous phase was separated and extracted three times with ca. 30 ml ethyl acetate. The combined organic phases were washed with brine

20 containing 1 % of NaOH, dried over MgSO<sub>4</sub> (anhydrous) and the solvent was evaporated in vacuo. The residue was purified by flash chromatography (SiO<sub>2</sub>,

- 45 -

hexane/ethyl acetate) to afford the pure crystalline aminohydroxylation product. In cases where regioisomeric products could be formed yields refer to a mixture of the two regioisomeres. Crystallization from ethyl acetate/ hexane furnished the enantiomerically pure (>99 %ee) N-aryl/alkylsulfonyl protected amino alcohol.

**Preparation of the Chloramine M: 48 ( $\text{CH}_3\text{SO}_2\text{NCl}$ )**



Chloramine M can be synthesized readily from methanesulfonamide (Aldrich chemical company) by addition of the stoichiometric amount of sodium hydroxide and t-butylhypochlorite in water or methanol. This method was adapted from a procedure developed by Campbell et al. *Chem Rev.* **1978**, 78, 65, for the preparation of N-chloro-N-sodiocarbamates and proved to be general in the synthesis of N-chloro-N-sodio-aryl- and alkylsulfonamides. Chloramine M can be isolated

- 46 -

either as a stable salt or can be prepared in situ, preferable in large scale syntheses.

**Synthesis of chloramine M:** To an ice-cold stirred solution of 4.81 g (50 mmol) of methanesulfonamide and 2.0 g (50 mmol) sodium hydroxide in 40 mL of dry methanol is added very slowly 5.63 mL (5.4 g, 50 mmol) t-butylhypochlorite. The solution is stirred for 1h and dried in vacuo to afford the pure N-chloro,N-sodio-methanesulfonamide in quantitative yield (7.58 g).

CH<sub>3</sub>NSO<sub>2</sub>NaCl, MW: 151.54; Elementary analysis: calcd.: C 7.93, H 2.00, N 9.24, Na 15.17, Cl 23.39 found: C 8.03, H 2.08, N 9.24, Na 15.36, Cl 23.12

For the in situ generation of Chloramine M the preparation can be done in the sufficient amount of water required for the AA reaction by using the same protocol.

**General procedure for synthesis of hydroxysufonamides using Chloramine M (MeSO<sub>2</sub>NClNa) on a 1 mmol scale (as illustrated in figure 14 and tabulated in figure 15)**

To a well stirred solution of 40 mg of (DHQD)<sub>2</sub>PHAL (0.05 mmol, 0.05 eq) in 7.5 ml of n-propanol



- 47 -


(alternatively, a 1:1 mix of t-BuOH/water, acetonitrile/water or 1:1:1 ethanol/n-proanol/water can be used, depending upon optimization conditions) was slowly added a solution of 455 mg (3.0 mmol, 3.0 eq) of MeSO<sub>2</sub>NClNa in 7.5 ml of water, which resulted in a clear colorless solution. The substrate olefin (all commercially available from Aldrich, **figure 15**, 1.0 mmol, 1.0 eq ) and K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> (0.04 mmol, 0.04 eq) were subsequently added. Usually the reaction mixture turned green after some minutes and was stirred until color change to dark blue occurred (3-16 h), however colour changes are not generally observed. 10 ml of aqueous Na<sub>2</sub>SO<sub>3</sub> (sat.) were added to reduce the excess MeSO<sub>2</sub>NClNa. The aqueous phase was separated and extracted three times with ca. 30 ml ethyl acetate. The combined organic phases were dried over MgSO<sub>4</sub> (anhydrous) and the solvent was evaporated in vacuo. To determine the exact yield the residue was purified by flash chromatography (SiO<sub>2</sub>, hexane/ethyl acetate) to afford the pure crystalline aminohydroxylation product. In cases where regioisomeric products can be formed yields refer to a mixture of the two regioisomers.

Crystallization from ethyl acetate/ hexane furnished the enantiomerically pure (>99 %ee) methane sulfonyl protected amino alcohol.

For preparative purposes work-up and purification can be simplified. As the methanesulfonamide is insoluble in CH<sub>2</sub>Cl<sub>2</sub> and ether, but good soluble in aqueous solution (even in saturated aqueous NaCl solution) it can be removed extractively. It can also be crystallized out in CH<sub>2</sub>Cl<sub>2</sub> or CH<sub>2</sub>Cl<sub>2</sub>/hexane mixtures.

Alternatively it can be sublimed from the crude material at 80°C. Crystallization from ethyl acetate/ hexane could usually furnish the chemically and enantiomerically pure (>99 %ee) methane sulfonyl protected amino alcohol.

**Asymmetric aminohydroxylation in 1:1 acetonitrile/water (used for synthesis of acrylates and methacrylates as shown in figures 16 and 17).**



- 49 -


To a stirred solution of (DHQ)<sub>2</sub>-PHAL (0.11 g, 0.14 mmol, 5 mol%) in 20 mL of acetonitrile and 20 mL of water, in any convenient-sized glass vessel or vial, was added desired acrylate or methacrylates entries 1-10 (all commercially available from Aldrich, **figure 16 and figure 17**, 2.8 mmol), Chloramine-T trihydrate (2.42 g, 8.4 mmol, 3 eq) and K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> (41.6 mg, 0.112 mmol, 4 mol%). As the reaction proceeded to completion over the course of about one and half hours at room temperature, the color of the solution changed from yellow to pale green, then deep green and finally back to yellow. After addition of aqueous sodium sulfite (1.0 g in 15 mL H<sub>2</sub>O), the phases were separated, and the aqueous phase extracted with ethyl acetate (3x15 mL). The combined organic extracts were washed with brine, dried over MgSO<sub>4</sub> and the solvent concentrated to give the crude product, which also contains the p-toluenesulfonamide by-product produced upon the reduction of the excess Chloramine-T. Purification provides compounds as shown in figure 16, entries 1-10 with the indicated yields and conditions.

NOTE: Replacement of the 3 eq of Chloramine-T with 1.5

- 50 -

eq of Chloramine-T and 1.5 eq of Et<sub>4</sub>NOAc gives comparable results and reduces the amount of p-toluenesulfonamide by-product formed. This can greatly simplify product isolation, especially in cases where  
5 the product and the toluenesulfonamide have similar chromatographic mobilities.

General procedure for synthesis of compound 2 (figure 18):



**Compound 2:** T-butyl hypochlorite was slowly added to a well stirred solution of the desired sulfonamide (as obtained *vide supra*; 3.1 mmol, 3.1 eq) and 122 mg (3.05 mmol, 3.05 eq) of NaOH in 7.5 ml of water at room temperature. After 10 more minutes of stirring this solution was added dropwise to a solution of 40 mg (0.05 mmol, 0.05 eq) of (DHQ)<sub>2</sub>Phal or (DHQD)<sub>2</sub>Phal in 7.5 ml of MeCN (alternatively, a 1:1 mix of t-BuOH/water, n-propanol/water or 1:1:1 ethanol/n-propanol/water can be used, depending upon optimization conditions). Subsequently 190 mg (1.0 mmol, 1.0 eq) of methyl cinnamate (commercially available from Aldrich) and 14.7 mg (0.04 mmol, 0.04 eq) of K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> were added and the reaction mixture stirred at RT. After ca. 10 min all of the K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> was dissolved and the color of the reaction mixture turned to green. Stirring

- 52 -


was continued until the green color of the reaction mixture had turned to yellow.

10 ml of aqueous  $\text{Na}_2\text{SO}_3$  (sat.) were added to reduce excess Chloramine. The aqueous phase was separated and  
5 extracted three times with ca. 30 ml ethyl acetate. The combined organic phases were washed with brine containing 1 % of NaOH, dried over  $\text{MgSO}_4$  (anhydrous) and the solvent was evaporated in vacuo. The residue was purified by flash chromatography ( $\text{SiO}_2$ ,

10 hexane/ethyl acetate) to afford the pure crystalline aminohydroxylation product. In cases where regioisomeric products could be formed yields refer to a mixture of the two regioisomeres. Crystallization from ethyl acetate/ hexane furnished the  
15 enantiomerically pure (>99 %ee) N-aryl/alkylsulfonyl protected amino alcohol.

Synthesis of  $\beta$ -hydroxy- $\alpha$ -N-aryl/alkylsulfonyl protected aminoacids 62 or 63 via aziridine intermediate 61

(figure 18):



**Compounds 62 and 63:** To the AA product 2 (2.15 mmol), in a THF solution (0.10 M), was added  $\text{P(Ph)}_3$  (1.1 equivalents triphenylphosphine) and diethyl azodicarboxylate (1.1 equivalents, all commercially available from Aldrich). The mixture was next stirred at room temperature for 1 hour and then worked up according to the procedure of Mitsunobu et al.

15 *Tetrahedron Letters*, **1989**, 5709. The resulting aziridine (0.302 mmol) was dissolved in a 6:4 v/v mixture of 1,4-dioxane/ $\text{H}_2\text{O}$  and 0.03 mL of TFA (trifluoroacetic acid) was added as the catalyst. The reaction was then run at 100 °C for 24 °C. The mixture was diluted with ethylacetate and separated from the aqueous phase. The aqueous phase was separated and extracted three times with ca. 30 ml ethyl acetate. The

20

- 54 -

combined organic phases were washed with brine containing 1 % of NaOH, dried over MgSO<sub>4</sub> (anhydrous) and the solvent was evaporated in vacuo. The residue was purified by flash chromatography (SiO<sub>2</sub>,  
5 hexane/ethyl acetate) to afford the pure crystalline aminohydroxylation product. In case where regioisomeric products are formed, crystallization from ethyl acetate/ hexane furnishes the enantiomerically pure (>99 %ee)  $\beta$ -hydroxy- $\alpha$ -N-aryl/alkylsulfonyl protected  
10 aminoacid **62** or **63**.



- 55 -

What is claimed is:

1. An improved method for converting an olefinic substrate to an asymmetric hydroxylamine product by asymmetric addition of a nitrogen source and a hydroxyl radical to the olefinic substrate, the method being of a type which employs a reaction solution which includes osmium as a catalyst, a chiral ligand for enantiomerically directing said asymmetric addition, the olefinic substrate being present and soluble at a stoichiometric concentration within the reaction solution, the osmium being present and soluble within the reaction solution at a catalytic concentration, wherein the improvement comprises the following substeps:


Substep A: said asymmetric addition is performed using a sulfonamide as the nitrogen source for forming an asymmetric hydroxysulfonamide intermediate; and then:

Substep B: said conversion is completed by deprotecting the asymmetric hydroxysulfonamide intermediate in said Substep A for forming the asymmetric hydroxylamine product.

2. A method for converting an olefinic substrate to an asymmetric hydroxylamine product as described in claim 1 wherein the sulfonamide is represented by the following structures:

30

- 56 -





wherein R is a radical selected from the group consisting of cyano, phenyl, 4-methyl-phenyl-, 4-methyl-O-phenyl-, methyl-, phenyl-CH<sub>2</sub>-, 4-NO<sub>2</sub>-phenyl-, 2-NO<sub>2</sub>-phenyl-2-naphthyl-, 1-naphthyl-, dansyl-, -O-(C<sub>1-6</sub>-alkyl), pyrrole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrolizine, quinazoline, quionline, thiophene and -(CH<sub>2</sub>)<sub>n</sub>-X wherein X is a radical selected from the group consisting of chloride, fluoride, iodide, phenyl, 4-methyl-phenyl-, 4-methyl-O-phenyl-, methyl-, phenyl-CH<sub>2</sub>-, 4-NO<sub>2</sub>-phenyl-, 2-NO<sub>2</sub>-phenyl-2-naphthyl-, 1-naphthyl-, dansyl-, pyrrole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrolizine, quinazoline, quionline and thiophene, wherein 1 ≤ n ≤ 6.

3. A method for converting an olefinic substrate to an asymmetric hydroxysulfonamide product comprising the step of:

catalyzing an asymmetric addition to the olefinic substrate of a sulfonamidyl radical and a hydroxyl radical by means of an osmium catalyst, said catalysis occurring in the presence of a chiral ligand for enantiomerically directing the asymmetric addition.

- 57 -

4. A method for converting an olefinic substrate to an asymmetric hydroxylamine product as described in claim 3 wherein the sulfonamide is represented by the following structures:



wherein R is a radical selected from the group consisting of cyano, phenyl, 4-methyl-phenyl-, 4-methyl-O-phenyl-, methyl-, phenyl-CH<sub>2</sub>-, 4-NO<sub>2</sub>-phenyl-, 2-NO<sub>2</sub>-phenyl-2-naphthyl-, 1-naphthyl-, dansyl-, -O-(C<sub>1-6</sub>-alkyl), pyrrole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrolizine, quinazoline, quionline, thiophene and -(CH<sub>2</sub>)<sub>n</sub>-X wherein X is a radical selected from the group consisting of chloride, fluoride, iodide, phenyl, 4-methyl-phenyl-, 4-methyl-O-phenyl-, methyl-, phenyl-CH<sub>2</sub>-, 4-NO<sub>2</sub>-phenyl-, 2-NO<sub>2</sub>-phenyl-2-naphthyl-, 1-naphthyl-, dansyl-, pyrrole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrolizine, quinazoline, quionline and thiophene, wherein 1 ≤ n ≤ 6.

5. A method for converting an olefinic substrate to an asymmetric hydroxysulfonamide product as described in claim 3 wherein the sulfonamide is a chloramine compound.

5 6. A method for converting an olefinic substrate to an asymmetric hydroxysulfonamide product as described in claim 3 wherein said asymmetric addition occurs in a co-solvent mixture containing an organic component and an aqueous component.

10 7. A method for converting an olefinic substrate to an asymmetric hydroxysulfonamide product as described in claim 6 wherein the organic component of the solvent is selected from the group consisting of acetonitrile, tert-butanol, and n-propanol.

15 8. A method for converting an olefinic substrate to an asymmetric hydroxysulfonamide product as described in claim 6 wherein the aqueous and organic components of the co-solvent are each approximately 50% on a volume basis.

20 9. A method for converting an olefinic substrate to an asymmetric hydroxysulfonamide product as described in claim 3 wherein said catalysis occurs substantially in the absence of an ancillary metal salt.

25 10. A method for converting an olefinic substrate to an asymmetric hydroxysulfonamide product as described in claim 9 wherein the ancillary metal salt is selected from the group consisting of silver salts and mercury salts.

1/17




Figure 1

2/17




Figure 2

3/17




Figure 3

4/17













Entry	Substrate	Product [a]	%ee			Yield (%)	Time (h)	m.p. (°C) [b]	[α] <sub>D</sub> <sup>25</sup> [b]
			(DHQD) <sub>2</sub> -PHAL [b]	(DHQD) <sub>2</sub> -PHAL [c]	(DHQD) <sub>2</sub> -PHAL [c]				
1			81 (99)	71	64	3	154-155	+19.8 (c = 0.50)	
2			74	60	52	1.5	oil	-20.3 (c = 1.25)	
3			77 (93)	53	65	3	140-141	-7.9 (c = 0.63)	
4 [d]			62 (99)	50	52	14	167-168	-15.9 (c = 0.43)	
5			33 (99)	48	48	3	227-228	+53.0 (c = 0.11)	
6			45 (99)	36	64	6	117-119	+1.8 (c = 0.60)	

Figure 4



5/17





Figure 5

6/17

Substrate	Product	% ee (DHQ) <sub>2</sub> -PHAL	Yield (%)	Time (h)
		82(89 [a])	60(51 [a])	3
		64(99 [b])	78(50 [b])	3
		50	57	2.5

Figure 6

7/17



*Conditions:*

5% (DHQD)<sub>2</sub>PHAL  
4% K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub>  
3 eq TsNCINa · 3H<sub>2</sub>O  
EtOH(5)/*n*-Propanol(3)/H<sub>2</sub>O(5)  
Room temperature, 5 hr

Figure 7

8/17





Figure 8


9/17



R = 4-Me-Ph-, 4-MeOPh, Me, Ph-CH<sub>2</sub>-, 4-NO<sub>2</sub>-Ph-, 2-NO<sub>2</sub>-Ph-, 2-Naphthyl, 1-Naphthyl, Dansyl or derivatives selected from the following functional groups: acyclic or cyclic hydrocarbons, hydroxyl compounds, ethers, protected amines, carbonyl compounds, esters or carboxylic acids, n-alkyl, pyrans, pyrroles, various heterocycles including: pyrazines, pyrazoles, pyridazines, pyridines, pyrimidines, pyrrolizines, quinazolines, quionlines, thiophenes, silanes, CH<sub>n</sub>X where X=OR<sub>1</sub>, halogens, aromatic rings, heterocycles, silyl groups and n=1 to 2.

Figure 9

10/17




$R_1$  = acyclic or cyclic hydrocarbons, heterocycles, hydroxyl compounds, ethers, protected amines, sulfides, carbonyl compounds, acrylates, substituted acrylates, esters or carboxylic acids

$R_2$  = combination of  $R_1$

$R_3$  = 4-Me-Ph-, 4-MeOPh, Me, Ph-CH<sub>2</sub>-, 4-NO<sub>2</sub>-Ph-, 2-NO<sub>2</sub>-Ph-, 2-Naphthyl, 1-Naphthyl, Dansyl or derivatives selected from the following functional groups: acyclic or cyclic hydrocarbons, hydroxyl compounds, ethers, protected amines, carbonyl compounds, esters or carboxylic acids, n-alkyl, pyrans, pyrroles, various heterocycles including: pyrazines, pyrazoles, pyridazines, pyridines, pyrimidines, pyrrolizines, quinazolines, quionlines, thiophenes, silanes, CH<sub>n</sub>X where X=OR<sub>1</sub>, halogens, aromatic rings, heterocycles, silyl groups and n=1 to 2.

Figure 10

11/17



R = 4-Me-Ph-  
 4-MeO-Ph-  
 Me-  
 Ph-CH<sub>2</sub>-  
 TMS-CH<sub>2</sub>-CH<sub>2</sub>-  
 4NC<sub>2</sub>Ph -  
 2-Naph.  
 1-Naph.  
 Dansyl

Figure 11








12/17

	R-SO <sub>2</sub> -NH <sub>2</sub>	time [h]	%ee	regioselectivity	yield* [%]
28:29	4-Me-Ph-	2	66	80 : 20	
30:31	4-MeO-Ph-	2	58	65 : 35	
32:33	Me-	4	80	83 : 17	
34:35	Ph-CH <sub>2</sub> -	8	85	8 : 2	38
36:37	TMS-CH <sub>2</sub> -CH <sub>2</sub> -	2	70	83 : 17	48
38:39	4-NO <sub>2</sub> -Ph-	6	67	81 : 19	
40:41	2-NO <sub>2</sub> -Ph-	6	70	72 : 25	
42:43	2-Naph.	3	79		50
44:45	1-Naph.	4	62	96 : 4	
46:47	Dansyl	5	(50)	96 : 4	

Figure 12



13/17



X = OR, Cl, aromatic rings .....

Figure 13

14/17





Figure 14

15/17

Substrate	Product	(DHQD) <sub>2</sub> -PHAL(DHQD) <sub>2</sub> -PHAL	Yield <sup>2</sup> (%)	Time (h)	m.p. (°C)	[α] <sub>D</sub> <sup>25</sup> [c]
%ee						
		(81)	(71)	(64)		
		(66)	(1)	(1)		
		95 (77)	94 (53)	63 (65)		
		75 (62)	82 (50)	71 (51)		
		80	82	63	116-117	
		(45)	(36)	(64)		

Figure 15

# AA of Acrylates and Methacrylates




Entry	R	R'	ee [%] <sup>a</sup>
1	Me	H	42 (38)*
2	Et	H	46
3	<i>n</i> -Hexyl	H	47
4	<i>i</i> -Bu	H	40 (30)*
5	<i>c</i> -Hexyl	H	49.5
6	<i>t</i> -Bu	H	56 (37)*
7	<i>t</i> -Bu	H	70** (57)***
8	Stearyl	H	-
9	Me	Me	9
10	<i>t</i> -Bu	Me	32 (18)*

Figure 16

17/17

# AA of *t*-Butyl Acrylate



Std. Conditions		56 % ee, (54 %)
Std. Conditions	+ NaCl (heterogen.)	54 % ee
Std. Conditions	+ 0 °C	53 % ee
Std. Conditions	+ 1.5 eq. CT	53 % ee
Std. Conditions	+ 4 % "Os" + 2 % Ligand	50 % ee
Std. Conditions	+ <i>t</i> BuOH / H <sub>2</sub> O	56 % ee *
Std. Conditions	+ EtOH / H <sub>2</sub> O	16.9 % ee *
Std. Conditions	+ 0.5 % "Os" + 0.5 % Ligand	42 % ee
Std. Conditions	+ 0.8 % "Os" + 1 % (DHQ) <sub>2</sub> -DPP Ligand	59 % ee
Std. Conditions	+ (DHQ) <sub>2</sub> -DPP Ligand	70 % ee

\* Low yield

Std. Conditions:

(DHQ)<sub>2</sub>PHAL (5 %), K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> (4 %) Chloramine T (3 eq.)

Figure 17

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/08593

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07C 315/00

US CL : 562/12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 562/12

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
NoneElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
APS, CAS ONLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Catalytic Asymmetric Dihydroxylation of Tetrasubstituted Olefins, Journal of American Chemical Society, Vol. 115, No. 18 pages 8463-8464, Morikawa et al. See entire document.	1-10



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

10 SEPTEMBER 1997

Date of mailing of the international search report

23 OCT 1997

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SAMUEL BARTS

Telephone No. (703) 308-1235



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C07C 315/00	A1	(11) International Publication Number: <b>WO 97/44316</b>
		(43) International Publication Date: 27 November 1997 (27.11.97)

(21) International Application Number: PCT/US97/08593

(22) International Filing Date: 21 May 1997 (21.05.97)

(30) Priority Data:  
08/651,819 21 May 1996 (21.05.96) US(71) Applicant: THE SCRIPPS RESEARCH INSTITUTE [US/US];  
10550 North Torrey Pines Road, La Jolla, CA 92037 (US).(72) Inventors: SHARPLESS, K., Barry; 7902 Roseland Drive, La  
Jolla, CA 92037 (US). LI, Guigen; 8450-D Via Mallorca, La  
Jolla, CA 92037 (US). CHANG, Han-Ting; 12550 Carmel  
Creek Road No. 93, San Diego, CA 92130 (US).(74) Agent: LEWIS, Donald, G.; The Scripps Research Institute,  
10550 North Torrey Pines Road, TPC-8, La Jolla, CA 92037  
(US).(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR,  
BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,  
GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,  
PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT,  
UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW,  
SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD,  
RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES,  
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD,  
TG).**Published***With international search report.**Before the expiration of the time limit for amending the  
claims and to be republished in the event of the receipt of  
amendments.*

(54) Title: CATALYTIC ASYMMETRIC AMINOHYDROXYLATION OF OLEFINS WITH SULFONAMIDES

## (57) Abstract

$\beta$ -Hydroxyamines and  $\beta$ -hydroxysulfonamides are synthesized from olefin substrates by means of a catalyzed asymmetric addition reaction. The addition reaction is catalyzed by osmium and is co-catalyzed by chiral ligands. The chiral ligands, in addition to being co-catalysts with the osmium, also serve to direct the addition reaction regioselectively and enantioselectively. Divalent ligands are preferred over monovalent ligands because of their enhanced regio- and enantio-selectivity. Sulfonamides are employed as an oxidant nitrogen source for the production of  $\beta$ -hydroxysulfonamides. Excellent yields and enantiomeric efficiencies are achieved with co-solvents containing a 50/50 (v/v) mixtures of water and organic solvent.  $\beta$ -Hydroxyamines are obtained by deprotecting the corresponding  $\beta$ -hydroxysulfonamides.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						



CATALYTIC ASYMMETRIC AMINOHYDROXYLATION  
OF OLEFINS WITH SULFONAMIDES

Specification

5     Field of Invention:

          The invention relates to the regio-selective and enantio-selective conversion of olefins to  $\beta$ -hydroxyamines and  $\beta$ -hydroxysulfonamides. More particularly, the invention relates to catalytic asymmetric additions or aminohydroxylations of olefins and other unsaturated substrates using sulfonamide as an oxidizing agent in the presence of an osmium catalyst and a chiral ligand.

15     Background:

          The  $\beta$ -hydroxyamine group is a common motif found in biologically active molecules. For example, the C-13 side-chain of taxol includes a  $\beta$ -hydroxyamine group and is known to be essential for the biological activity of taxol. Hence synthesis of the side-chain and its analogs is a subject of significant recent interest. Modifications of the taxol side-chain are an important aspect of the structure-activity-relationship (SAR). Among numerous synthetic approaches, the asymmetric catalytic methods hold special interest. The catalytic asymmetric dihydroxylation (AD) and asymmetric epoxidation (AE) have been successfully applied in syntheses of the C-13 side-chain. (Denis, J.-N., et al., Journal of Organic Chemistry, 51(1986) 46; Denis, J.-N., et al., Journal of Organic Chemistry, 55(1990) 1957; Deng, L. and

- 2 -

Jacobsen, E. N.. Journal of Organic Chemistry, 57(1992) 4320; and Wang, Z.-M., et al., Journal of Organic Chemistry, 59(1994) 5104).

5 Sharpless et al. first demonstrated that  $\beta$ -hydroxysulfonamides could be obtained using either stoichiometric or catalytic amounts of 1% osmium tetraoxide in the presence of 1.5 - 5 equivalents of Chloramine-T trihydrate ( $\text{TsSO}_2\text{NClNa} \cdot 3\text{H}_2\text{O}$ , Ts = tosylate; commercially obtained) to effect cis addition of a  
10 hydroxyl (OH) and an arylsulfonamide moiety ( $\text{Ar-SO}_2\text{NH}$ ) across a mono or disubstituted olefinic linkages (Sharpless et. al. *J. Org. Chemistry* **1976**, 41, 177).

Two procedures were developed to effect hydroxyamination of olefins using sulfonamides.  
15 (Sharpless et al. *Org. Syn.* **1980**, 61, 85). The first procedure used phase transfer catalysis conditions at 55-60 °C with 1%  $\text{OsO}_4$ , 1:1 v/v, 0.20 Molar  $\text{CHCl}_3/\text{H}_2\text{O}$ , and benzyltriethylammonium chloride as the phase transfer catalyst. The chloramine T-trihydrate  
20 ( $\text{TsSO}_2\text{NClNa} \cdot 3\text{H}_2\text{O}$ ) was either added directly or formed in situ in water; this solution was then directly used in the phase transfer mixture. The in situ procedure, for generating the chloramine salts, involved stirring a suspension of the arylsulfonamide with an equivalent of  
25 sodium hypochlorite (Clorox) until a homogenous solution was obtained. The yields were comparable with those obtained with isolated chloramine salts and the procedure was found most effective for monosubstituted and 1,2 disubstituted olefins. The phase transfer  
30 method, however, gave poor results with trisubstituted

and 1,1-disubstituted olefins and the procedure did not succeed with diethyl fumarate and 2-cyclohexen-1-one. Sharpless et al. *J. Org. Chem.* **1978**, 43, 2544.

5 A second procedure was carried out in tert-butyl alcohol at 55- 60 °C with 1% OsO<sub>4</sub>, silver nitrate (with or without) and commercially obtained chloramine T-trihydrate (TsSO<sub>2</sub>NClNa·3H<sub>2</sub>O) which provided the only source of water. The procedure did not succeed with tetramethylethylene and cholesterol, and negative  
10 results were found with most hindered tri- and tetrasubstituted olefins. Sharpless et. al. *J. Org. Chemistry* **1976**, 41, 177; Sharpless et al. *Org. Syn.* **1980**, 61, 85. The addition of divalent metal salts such as AgNO<sub>3</sub> and Hg(NO<sub>3</sub>)<sub>2</sub> improved some reactions, however,  
15 other reactions suffered deleterious effects from the addition of the metal salts. Sharpless et al. *J. Org Chem.* **1978**, 43, 2544; Sharpless et. al. *J. Org. Chemistry* **1976**, 41, 177.

Further elaboration on either procedure showed  
20 that other sulfonamide derivatives (ArSO<sub>2</sub>NClNa) could be successfully employed in addition to chloramine T, where Ar = phenyl, o-tolyl, p-chlorophenyl, p-nitrophenyl, and o-carboalkoxyphenyl. Sharpless et al. *J. Org. Chem.* **1978**, 43, 2546.

25 Neither the phase transfer catalyst or tert-butyl alcohol procedures succeeded with tetramethyl ethylene, 2,3-dimethyl-2-octene, diethyl fumarate, or 2-cyclohexen-1-one. Negative results were also obtained with most hindered tri- and tetrasubstituted olefins.  
30 Herranz E., MIT Ph.D. Thesis, **1979**, 33.

Solvent conditions for the synthesis of the hydroxysulfonamides included organic solvents such as acetonitrile, tert-butyl alcohol, isopropyl alcohol and chloroform which was in contact with the aqueous phase in the phase transfer catalyst procedure.

The tert-butyl alcohol procedure (including other solvents used) was not run with added water; the phase transfer catalyst (PTC) procedure required a biphasic mixture of 1:1 v/v chloroform/water. Recently, however, an improvement was reported which used a 1:1 ratio of organic solvent to water in a homogeneous, rather than a biphasic solution or organic solvent with small amounts of water. These conditions were found to provide optimum enantioselectivity, regioselectivity and improved yields from either the previously described t-butyl alcohol or PTC conditions. Sharpless et al. *Angew. Chemie Intl Ed.* **1996**, 35, 451.

The use of chiral ligands with sulfonamides provides enantioselectivity and has been observed to both accelerate and decelerate the rate of catalysis. The hydroxysulfonamide process is a stereoselective *cis* process. The presence of ligands also has a dramatic effect on the regioselectivity. In a study with no ligand present with methyl cinnamate, the two regioisomers were present in a 2:1 ratio. With the addition of ligand, the ratio was improved to 5:1 or greater. Another positive effect of the ligand was its ability to suppress formation of diol by-product. *Angew. Chemie Intl Ed.* **1996**, 35, 451.

Preferred ligands for use with sulfonamides have included the use of monovalent cinchona alkaloids or

the bivalent phthalazine based, commercially available (DHQ)<sub>2</sub>PHAL and (DHQD)<sub>2</sub>PHAL alkaloids. Sharpless et al. *Angew. Chemie Intl Ed.* **1996**, 35, 451.

5 Temperature conditions for the hydroxysulfonamide asymmetric aminohydroxylations have varied from 60 °C to 25 °C for reactions including sulfonamides, auxiliary salts, ligands, phase transfer catalysts and stoichiometric or catalytic osmium species, primarily in organic solvents with small amounts of water.

10 Recently, it has been shown that temperature can be lowered to 0 °C while running the reaction, to obtain product by filtration; many hydroxysulfonamides tend to be highly crystalline.

15 Cleavage of the sulfonamides, to free aminoalcohols, have been accomplished via standard deprotection conditions including dissolving metals (Na, NH<sub>3</sub>; Sharpless et al *J. Org. Chem* **1976**, 41, 177) and HBr, acetic acid and phenol (Fukuyama et al. *Tetrahedron Lett.* in press).

20 What is needed is an improved method for catalyzing the symmetric aminohydroxylation of olefins, wherein the improvement enhances the yields, enantiomeric efficiency, and the regio-selectivity while reducing material and labor costs.

25

Summary of the Invention:

The invention is directed to an improved method for converting olefinic substrates to asymmetric β-hydroxysulfonamide products. The method of the invention employs an asymmetric addition reaction

30

involving the asymmetric addition of a nitrogen source and a hydroxyl radical to the olefinic substrate.

Enhanced yields, regioselectivity, and

enantioselectivity may be achieved according to

the method of the invention. The asymmetric addition

reaction is carried out in a reaction solution which

includes the olefinic substrate, an osmium catalyst, a

chiral ligand for enantiomerically and regioselectively

directing the asymmetric addition, and a nitrogen

source. The olefinic substrate is present and soluble

within the reaction solution in stoichiometric amounts.

The osmium is present within the reaction solution in

catalytic amounts. One aspect of the improvement is

directed to the use of a sulfonamide as the nitrogen

source for forming an asymmetric hydroxysulfonamide

intermediate. Preferred sulfonamides include

chloramine compounds. Preferred reaction solutions

include co-solvent mixtures containing both an organic

component and an aqueous compound. Preferred organic

components include acetonitrile, tert-butanol, and n-

propanol. In a preferred co-solute, each of the

organic and aqueous components is approximately 50% on

a volume basis. In a preferred mode, the asymmetric

hydroxysulfonamide reaction occurs in the substantial

absence of ancillary salts, including silver salts and

mercury salts. After the hydroxysulfonamide

intermediate is formed, the asymmetric hydroxylamine

product may be obtained by deprotecting the asymmetric

hydroxysulfonamide intermediate for forming the

asymmetric hydroxylamine product.

Description of Figures

Figure 1 illustrates the synthesis of  $\alpha$ -hydroxy-  
 $\beta$ -sulfonamide compounds **2** and **ent-2**. The synthetic  
5 conditions are as follows:  $\text{K}_2\text{OsO}_2(\text{OH})_4$ , 4%;  $(\text{DHQ})_2\text{-PHAL}$   
or  $(\text{DHQD})_2\text{-PHAL}$ , 5%;  $\text{TsNClNa} \cdot 3\text{H}_2\text{O}$ , 3 eq.;  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$  or  
 $t\text{-BuOH}/\text{H}_2\text{O}$ , v/v=1:1; Room temp., 3 h, 0.07 M in olefin.

Figure 2 illustrates the synthesis of  $\alpha$ -hydroxy-  
10  $\beta$ -sulfonamide compounds **2** in 1:1 v/v  $t\text{BuOH}/\text{H}_2\text{O}$  and  
represents a solution-to-solid catalytic AA using only  
2.5 mol% ligand and 2.0 mol% osmium catalyst. Product  
**2** crystallizes as it is formed, isolation includes only  
filtration of the crude mixture. The synthetic  
15 conditions are as follows: Methyl cinnamate **1**,  
 $\text{K}_2\text{OsO}_2(\text{OH})_4$ , 2.0%;  $(\text{DHQ})_2\text{-PHAL}$ , 2.5%;  $\text{TsNClNa} \cdot 3\text{H}_2\text{O}$ , 3.5  
eq.;  $t\text{BuOH}/\text{H}_2\text{O}$ , v/v=1:1; Room temp., 3 h, 0.07 M in  
olefin; 69% yield, 82% ee.

Figure 3 illustrates the removal of the sulfonamide and  
20 methyl ester protecting groups from substrate **2** to form  
intermediate **3** which is subsequently converted to the  
taxol side chain via amide formation (step iii). The  
synthetic conditions are as follows: (i)  $\text{HBr-HOAc}$ ,  
25 phenol, 75 °C; (ii) Amberlite 120 resin; (iii)  $\text{PhCOCl}$ ,  
2N  $\text{NaOH}$ ,  $\text{H}_2\text{O}$ .

Figure 4 tabulates a series of products formed from  
catalytic asymmetric aminohydroxylation in 1:1  
30  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$  (procedure 1).

- 8 -

[a] All absolute configurations have been determined, see experimental procedure. [b] Numbers in parentheses are after recrystallizations from methanol (in some cases, it is the mother liquor which is enantioenriched when the racemate crystallizes preferentially - in the case of methylcinnamate only 2.5 mol% ligand and 2.0 mol% osmium catalyst were used, due to the preferential crystallization); the melting points and optical rotations (in 95% ethanol) are for the highest ee samples in the (DHQ)<sub>2</sub>-PHAL column of Table 1. [c] The ee's in this column are for the products which are enantiomeric to those in the "Product" column. [d] 4:3 CH<sub>3</sub>CN/H<sub>2</sub>O was used as the solvent.

Figure 5 illustrates a suggested mechanism and reactive species formed via the generation of the  $\alpha$ -hydroxy- $\beta$ -sulfonamide **9** from cyclohexene and K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub>, 4%; (DHQ)<sub>2</sub>-PHAL or (DHQD)<sub>2</sub>-PHAL, 5%; TsNClNa.3H<sub>2</sub>O and 1:1 solvent mix.

Figure 6 tabulates a series of products formed from catalytic asymmetric aminohydroxylation in 1:1 t-BuOH/H<sub>2</sub>O (procedure 2).

[a] In this case, one half of the olefin was added at the beginning of the reaction and the rest was added in portions over 45 min starting one hour later. [b] The minor enantiomer is completely removed by two triturations with ethyl acetate which leaves a 50% yield of enantiopure (S,S)-**5**.



Figure 7 illustrates the effects of changing conditions on the synthesis of  $\alpha$ -hydroxy- $\beta$ -sulfonamide compound **11**. An electron withdrawing substituent on the phenyl ring of methylcinnamate via *p*-nitro-methylcinnamate, coupled with a 3 solvent mix (EtOH(5)/*n*-propanol(3)/H<sub>2</sub>O(5) and 5 hour reaction time, increases enantiomeric excess to 94%, regioselectivity to 31:1 and yield to 86%. The synthetic conditions are as follows: K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub>, 4%; (DHQ)<sub>2</sub>-PHAL or (DHQD)<sub>2</sub>-PHAL, 5%; TsNClNa.3H<sub>2</sub>O, 3 eq.; (EtOH(5)/*n*-propanol(3)/H<sub>2</sub>O(5); Room temp., 5 h, 0.07 M in olefin.

Figure 8 shows a series of cinnamate derivatives which illustrate the effects of changing conditions. An electron withdrawing substituent on the phenyl ring of methylcinnamate as *p*-methoxy **12**, *p*-bromo **14**, *p*-nitro **16**, *p*-nitro **10**, *o*-nitro **18**, *m*-nitro **20**, *o*-methyl **22**, 2,5 dimethyl **24**, or 2,5 dimethoxy **26**, coupled with a solvent mix of CH<sub>3</sub>CN/H<sub>2</sub>O, *n*-propanol/H<sub>2</sub>O, *t*-BuOH/H<sub>2</sub>O, v/v=1:1 or (EtOH(5)/*n*-propanol(3)/H<sub>2</sub>O(5) provided the indicated enantiomeric excesses, regioselectivities and yields. The synthetic conditions were as follows: K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub>, 4%; (DHQ)<sub>2</sub>-PHAL or (DHQD)<sub>2</sub>-PHAL, 5%; TsNClNa.3H<sub>2</sub>O, 3 eq.; indicated solvent mix; room temp., 3 h, 0.07 M in olefin.

Figure 9 illustrates a general synthesis of *N*-chloro-*N*-sodio-*R*-sulfonamides **RSO<sub>2</sub>NClNa**, where *R* consists of one of the following groups: 4-Me-Ph-, 4-MeOPh, Me, Ph-CH<sub>2</sub>-, 4-NO<sub>2</sub>-Ph-, 2-NO<sub>2</sub>-Ph-, 2-Naphthyl, 1-Naphthyl,

Dansyl or derivatives selected from the following functional groups: acyclic or cyclic hydrocarbons, hydroxyl compounds, ethers, protected amines, carbonyl compounds, esters or carboxylic acids, n-alkyl, pyrans, pyrroles, various heterocycles including: pyrazines, pyrazoles, pyridazines, pyridines, pyrimidines, pyrrolizines, quinazolines, quionlines, thiophenes, silanes,  $\text{CH}_n\text{X}$  where  $\text{X}=\text{OR}_1$ , halogens, aromatic rings, heterocycles, silyl groups and  $n=1$  to 2.

Figure 10 illustrates a general aminohydroxylation reaction (AA) for the olefin  $\text{R}_1\text{CHCHR}_2$  using N-chloro-N-sodio- $\text{R}_3$ -sulfonamides  $\text{R}_3\text{SO}_2\text{NClNa}$  and various reaction conditions including  $\text{K}_2\text{OsO}_2(\text{OH})_4$ , 2-4%;  $(\text{DHQ})_2\text{-PHAL}$  or  $(\text{DHQD})_2\text{-PHAL}$ , 2.5-5%;  $\text{TsNClNa} \cdot 3\text{H}_2\text{O}$ , 3-5 eq.; indicated solvent mixes including  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ , n-propanol/ $\text{H}_2\text{O}$ , t-BuOH/ $\text{H}_2\text{O}$ , v/v=1:1 or  $(\text{EtOH}(5)/\text{n-propanol}(3)/\text{H}_2\text{O}(5))$ ; room temp., 3-5 h, .01- 0.07 M in olefin.

$\text{R}_1$  = acyclic or cyclic hydrocarbons, heterocycles, hydroxyl compounds, ethers, protected amines, sulfides, carbonyl compounds, acrylates, substituted acrylates, esters or carboxylic acids.

$\text{R}_2$  = combination of  $\text{R}_1$

$\text{R}_3$  = 4-Me-Ph-, 4-MeOPh, Me, Ph- $\text{CH}_2$ - , 4- $\text{NO}_2$ -Ph-, 2- $\text{NO}_2$ -Ph-, 2-Naphthyl, 1-Naphthyl, Dansyl or derivatives

selected from the following functional groups: acyclic or cyclic hydrocarbons, hydroxyl compounds, ethers, protected amines, carbonyl compounds, esters or carboxylic acids, n-alkyl, pyrans, pyrroles, various heterocycles including: pyrazines, pyrazoles, pyridazines, pyridines, pyrimidines, pyrrolizines,

quinazolines, quionlines, thiophenes, silanes,  $\text{CH}_n\text{X}$  where  $\text{X}=\text{OR}_1$ , halogens, aromatic rings, heterocycles, silyl groups and  $n=1$  to 2.

5 Figure 11 illustrates the catalytic asymmetric aminohydroxylation of isopropyl cinnamate by addition of *N*-chloro-*N*-sodio-*R*-sulfonamides or *in situ* generation of  $\text{R-SO}_2\text{NClNa}$  via  $\text{R-SO}_2\text{Cl}$ .  $\text{R} = 4\text{-Me-Ph-}$ , 4-MeOPh, Me, Ph-CH<sub>2</sub>- , 4-NO<sub>2</sub>-Ph-, 2-NO<sub>2</sub>-Ph, 2-Naphthyl, 1-Naphthyl, Dansyl or derivatives selected from the following functional groups: acyclic or cyclic hydrocarbons, hydroxyl compounds, ethers, protected amines, carbonyl compounds, esters or carboxylic acids, n-alkyl, pyrans, pyrroles, various heterocycles including: pyrazines, pyrazoles, pyridazines, pyridines, pyrimidines, pyrrolizines, quinazolines, quionlines, thiophenes, silanes,  $\text{CH}_n\text{X}$  where  $\text{X}=\text{OR}_1$ , halogens, aromatic rings, heterocycles, silyl groups and  $n=1$  to 2.

20 Figure 12 tabulates the catalytic asymmetric aminohydroxylation of isopropyl cinnamate by *in situ* generation of  $\text{R-SO}_2\text{NClNa}$  via  $\text{R-SO}_2\text{NH}_2$  to give compounds 28-47 with respective conditions indicated.  $\text{R} = 4\text{-Me-Ph-}$ , 4-MeOPh, Me, Ph-CH<sub>2</sub>- , 4-NO<sub>2</sub>-Ph-, 2-NO<sub>2</sub>-Ph, 2-Naphthyl, 1-Naphthyl, Dansyl or derivatives selected from the following functional groups: acyclic or cyclic hydrocarbons, hydroxyl compounds, ethers, protected amines, carbonyl compounds, esters or carboxylic acids, n-alkyl, pyrans, pyrroles, various heterocycles

**THIS PAGE BLANK (USPTO)**

including: pyrazines, pyrazoles, pyridazines,  
pyridines, pyrimidines, pyrrolizines, quinazolines,  
quionlines, thiophenes, silanes,  $\text{CH}_n\text{X}$  where  $\text{X}=\text{OR}_1$ ,  
halogens, aromatic rings, heterocycles, silyl groups  
and  $n=1$  to 2.

Figure 13 illustrates additional *N*-chloro-*N*-sodio-*R*-  
sulfonamides derivatives  $\text{R-SO}_2\text{NClNa}$  selected from the  
following functional groups: *R* = acyclic or cyclic  
hydrocarbons, hydroxyl compounds, ethers, protected  
amines, carbonyl compounds, esters or carboxylic acids,  
*n*-alkyl, alkynes (60) pyrans, pyrroles (54), various  
heterocycles including: nitriles (58), pyrazines,  
pyrazoles (55), pyridazines, pyridines (57), pyrimidines  
(59), pyrrolizines, quinazolines, quionlines,  
thiophenes, silanes,  $\text{CH}_n\text{X}$  where  $\text{X}=\text{OR}_1$ , halogens,  
aromatic rings, heterocycles, silyl groups and  $n=1$  to 2  
(56).

Figure 14 illustrates the AA (asymmetric  
aminohydroxylation) reaction of dimethylfumarate under  
conditions which utilize 3.0 equivalents of *N*-chloro-*N*-  
sodio-methanesulfonamide (Chloramine M) to achieve a  
98% ee (enantiomeric excess) and 62% overall yield of  
49.

Figure 15 tabulates the AA (asymmetric  
aminohydroxylation) for a series of substrates under  
conditions which utilize 3.0 equivalents of *N*-chloro-*N*-  
sodio-methanesulfonamide (Chloramine M). (1)

**THIS PAGE BLANK (USPTO)**

performing this reaction at 17 °C, the enantioselectivity was > 98%; (2) yields not optimized.

Figure 16 illustrates a series of products formed from the AA (asymmetric aminohydroxylation) of selected acrylates and methacrylates (entries 1-10). The synthetic conditions are as follows:  $K_2OsO_2(OH)_4$ , 4%;  $(DHQ)_2$ -PHAL or  $(DHQD)_2$ -PHAL, 5%;  $TsNClNa \cdot 3H_2O$  (chloramine T), 3 eq.;  $CH_3CN/H_2O$  or  $t$ -BuOH/ $H_2O$ , v/v=1:1; Room temp., 3 h, 0.07 M in olefin.

Figure 17 illustrates a series of products formed from the AA (asymmetric aminohydroxylation) of  $t$ -butyl acrylate. The synthetic conditions are as follows:  $K_2OsO_2(OH)_4$ , 4%;  $(DHQ)_2$ -PHAL or  $(DHQD)_2$ -PHAL, 5%;  $TsNClNa \cdot 3H_2O$  (chloramine T), 3 eq.;  $CH_3CN/H_2O$  or  $t$ -BuOH/ $H_2O$ , v/v=1:1; Room temp., 3 h, 0.07 M in olefin and indicated changes as noted with the respective enantiomeric excess (ee) listed

#### Detailed Description:

A synthetic method is disclosed herein for obtaining  $\beta$ -hydroxysulfonamides and  $\beta$ -hydroxyamines directly from olefins in enantiomerically enriched form. The new osmium-catalyzed asymmetric process is exemplified in Scheme 1 by the synthesis of the Taxol sidechain enantiomers (2 and **ent-2**) from methyl cinnamate (1). This catalytic aminohydroxylation (AA) is obviously a close relative of the catalytic asymmetric dihydroxylation (AD), see H. C. Kolb, et


- 14 -

al., Chem. Reviews 1994, 94, 2483. In fact, its stoichiometric analog was first reported in 1980 as a footnote in the initial report on the stoichiometric asymmetric dihydroxylation process, e.g., see note 22 in S. G. Hentges and K. B. Sharpless, J. Am. Chem. Soc. 1980, 102, 4263. Stoichiometric AA's have also been reported recently by H. Rubinstein and J.S. Svendsen, Acta Chem. Scand. 1994, 48, 439 and by C. Y. Park, Ph.D. thesis, Massachusetts Institute of Technology, Cambridge, MA, 1991. However, both the AD and the AA, being at first only stoichiometric reactions, were pushed aside by the titanium-catalyzed asymmetric epoxidation process (AE), also discovered in 1980. (T. Katsuki and K. B. Sharpless, J. Am. Chem. Soc. 1980, 102, 5974.) Ever since the discovery of the catalytic AD in 1987, we have tried to render the AA catalytic. (E. N. Jacobsen, et al., J. Am. Chem. Soc. 1988, 110, 1968.)

Initially, success was very limited. The first, albeit inefficient, asymmetric aminohydroxylations were performed by Christopher J. Burns and Declan Gilheanny in the Sharpless' laboratory at the Massachusetts Institute of Technology in 1987, unpublished results. It is disclosed herein how to run the reaction under conditions which allow the catalytic cycle to turnover at a useful rate. The process disclosed herein combines the AD's phthalazine ligands and the osmium-catalyzed aminohydroxylations. (See K. B. Sharpless, et al., Org. Chem. 1976, 41, 177; E. Herranz, et al., J. Org. Chem. 1978, 43, 2544; E. Herranz, et al., J. Am. Chem. Soc. 1978, 100, 3596; E. Herranz and K. B. Sharpless, J.



Org. Chem. 1980, 45, 2710; E. Herranz and K. B. Sharpless, Org. Synth. 1983, 61, 85; E. Herranz and K. B. Sharpless, Org. Synth. 1981, 61, 93; For Palladium-promoted aminohydroxylation (oxyamination) see: J. E. Bäckvall and E. E. Björkman, J. Org. Chem. 1980, 43, 2893; and J. E. Bäckvall, Tetrahedron Lett. 1975, 26, 2225.) Other than the asymmetric induction, the most dramatic effect of the alkaloid ligand is on the regioselectivity. In the original study (no ligand present) with methyl cinnamate (1) the C-3 sulfonamide isomer 2 and its regioisomer, with the sulfonamide substituent at C-2, were produced in a 2:1 ratio. In the present system this ratio is improved to 5:1 or greater. In fact, at the early stage (i.e. ~5% conversion) of the reaction with methyl cinnamate this ratio is > 20:1 and the enantiomeric purity of the major regioisomer (2) is about 95% ee. Both regioselectivity and enantioselectivity drop continuously as the reaction proceeds. This is tentatively attributed to intrusion of a "second cycle". Ethyl crotonate (entry 2, Table 1) benefits from this same ligand effect. Another positive effect of the ligand is its ability to suppress formation of the diol by-product, which in the absence of the ligand is substantial in this new system.



Scheme 1:  $\text{K}_2\text{OsO}_2(\text{OH})_4$ , 4%;  $(\text{DHQ})_2\text{-PHAL}$  or  $(\text{DHQD})_2\text{-PHAL}$ , 5%;  $\text{TsNClNa}\cdot 3\text{H}_2\text{O}$ , 3 eq.;  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$  or  $t\text{-BuOH}/\text{H}_2\text{O}$ , v/v=1:1; Room temp., 3 h, 0.07 M in olefin.

**Legend for Table 1:**

----- Catalytic asymmetric aminohydroxylation in 1:1  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$  (procedure 1). [a] All absolute configurations have been determined, see experimental procedure. [b] Numbers in parentheses are after recrystallizations from methanol (in some cases, it is the mother liquor which is enantioenriched when the racemate crystallizes preferentially); the melting points and optical rotations (in 95% ethanol) are for the highest ee samples in the  $(\text{DHQ})_2\text{-PHAL}$  column of Table 1. [c] The ee's in this column are for the

products which are enantiomeric to those in the "Product" column. [d] 4:3 CH<sub>3</sub>CN/H<sub>2</sub>O was used as the solvent.

Table 1 reveals that the process in its present form yields only modest enantioselectivities (33-81%). On the other hand, the first report on the catalytic AD did not look much better (20-88% ee) [1a] and this new process offers considerably more variables for optimization efforts. Even the present results are useful since hydroxysulfonamides tend to be highly crystalline, and can usually be raised to enatiopurity by recrystallization. This is the case for the Taxol side-chain derivative 2, which following deprotection by treatment with 33% HBr in acetic acid for 10 hours at 75 °C gives the enantiopure n -hydroxy- $\beta$ -amino acid in 70% yield. While the core functionality of toluenesulfonamide derivative 2 survives these strongly acidic conditions, many molecules would not. Indeed, the notorious problems associated with deprotection of sulfonamides are a serious concern for this AA process. Fortunately, there has been a breakthrough from the Fukuyama group (T. Fukuyama, et al., Tetrahedron Lett.

1995, 36, 6376.), which promises to make sulfonamide protection for nitrogen extremely popular. In any case, the vigorously acidic, yet successful conditions for deprotection of the Taxol side-chain precursor  
5 (vide supra) reveal that more molecules than previously imagined may tolerate the old brute-force approach for hydrolysis of aromatic sulfonamides.


Synthetic Protocols

**General experimental.** All reagents and solvents were purchased from commercial sources and used as received unless stated otherwise. All commercial chemicals were used without purification and their stoichiometries were calculated based on the reported purities from the manufacturer. (DHQD)<sub>2</sub>PHAL, 95% (hydroquinidine 1,4-phthalazinediyl diether), (DHQ)<sub>2</sub>PHAL, 97% (hydroquinine 1,4-phthalazinediyl diether), chloramine-T-hydrate 98% (N-chloro-p-toluenesulfonamide, sodium salt) are commercially available from Aldrich Chemical Company. Additionally, the (DHQ)<sub>2</sub> and (DHQD)<sub>2</sub> ligands can be prepared from the procedure of Sharpless et al. *J. Org. Chem.* **1992**, 57, 2768. Melting points were measured without correction with a Thomas-Hoover capillary apparatus. Optical rotations were recorded on an Autopol III polarimeter (Rudolph Research, Fairfield, N. J.). <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker AMX 400 instrument. Stoichiometries are calculated based on the purities reported by the manufacturer (trans-stilbene: 96%; Chloramine-T trihydrate: 98%).

- 20 -

The  $K_2OsO_2(OH)_4$  should be mauve rather than brown/black and should be dry for the best yields and ee's (the hygroscopic nature of the salt affects the amount of osmium dispensed). All new compounds gave satisfactory spectroscopic analyses ( $^1H$ -NMR, IR, HRMS). Enantiomeric excesses (ee's) were determined by HPLC using Chiracel columns (Daicel Chemical Industries) and isopropanol/hexane (v/v) mobile phases; the retention time of the major enantiomer from the  $(DHQ)_2$ -PHAL reaction is in italics. The vicinal hydroxysulfonamides derived from AA reactions using  $(DHQ)_2$ -PHAL as the chiral ligand were correlated to compounds of known absolute configuration by HPLC.

**Synthesis of (2R,3S)-(+)-Methyl-N-(p-toluenesulfonyl)-2-hydroxy-3-amino-3-phenyl-propionate (2) in t-BuOH (figures 1 and 2):**



**Compound 2.** To a 2 L round-bottom flask, equipped with

- 21 -

a mechanical stirrer and a thermometer, was added (DHQ)-PHAL (6.6 g, 2.5 mol%), t-BuOH (600 mL) and H<sub>2</sub>O (600 mL). The flask was immersed in a room temperature water bath. To the resulting homogeneous solution was  
5 added in order 290.4 g (1.01 mol) of Chloramine-T trihydrate (ca. 4/5 of the total added which is in 338 g, 1.18 mol), methyl cinnamate (27.2 g, 167.6 mmol, half of the total amount of olefin, which is 54.4 g, 0.33 mol; Aldrich chemical company) and potassium  
10 osmate(VI; Aldrich) (2.5 g, 2.0 mol%). As the reaction was stirred, the color changed from yellow to green in 15 min and then back to yellow after 90 min; TLC(EtOAc/Hexane, v/v = 4/6) revealed that the disappearance of olefin coincided with the return of  
15 the yellow color. The flask was then immersed in an ice bath (0 °C) for 20 min. (During this cooling, the crystals of precipitated product made their first appearance.) To this cold, stirred suspension the remainder of the Chloramine-T trihydrate (48.4 g, 0.168  
20 mol) and the second portion of methyl cinnamate (13.6 g, 84 mmol) was added. The ice bath was replaced by the room temperature water bath, and the new olefin charge

- 22 -


was consumed in about 45 min during which time the color changed as before from yellow to green and back to yellow again. The resulting mixture was cooled back to 0 °C for over 15 min and the third and last portion of methyl cinnamate (13.6 g, 84 mmol) was added. The reaction was returned to the room-temperature water bath and the remaining olefin was consumed in about 45 min with the above noted sequence of color changes. The flask was again immersed in an ice bath (0 °C) for about 20 min. Essentially all of the product precipitated out of solution and was isolated by filtration, washed twice with cold (ca 0 °C) 100 mL portions of t-BuOH/H<sub>2</sub>O (v/v = 1/1) to yield 81.1 g of (2R,3S)-(+)-methyl-N-(p-toluenesulfonyl)-2-hydroxy-3-amino-3-phenyl propionate (2) (69% yield, 82% ee, m.p. 147-148 °C; for racemic: m.p. 125-126 °C 4c).

A 6.3 g portion of this crude 2 was triturated with EtOAc at room temperature (1 x 75 mL, 1 x 35 mL and 2 x 20 mL), the solid triturand of 2 remaining after these triturations is of low ee and is discarded. Concentration of the combined triturates afforded 5.3 g of enantiomerically enriched 2 (58 % yield, 92% ee),



three recrystallizations from MeOH gave 3.2 g of enantiomerically pure product 2 (35% yield based on 1), m.p. 154-155 °C;  $[\alpha]_D^{25} = +19.8^\circ$  (c 0.5, 95% EtOH);  $^1\text{H}$  NMR (400 MHz, DMSO/ $\text{D}_2\text{O}$ )  $\delta$  2.23 (s, 3H), 3.45 (s, 3H), 4.17 (d,  $J = 4.0$  Hz, 1H), 4.65 (d,  $J = 4.0$  Hz, 1H), 7.08-7.19 (m, 8H), 7.40 (d,  $J = 8.2$  Hz, 2H);  $^{13}\text{C}$  NMR (100 MHz, DMSO)  $\delta$  171.8, 141.9, 138.4, 138.7, 128.9, 127.6, 127.3, 126.9, 126.4, 74.4, 60.1, 51.6, 20.9.

**Synthesis of (2R,3S)-(+)-Methyl-N-(p-toluenesulfonyl)-2-hydroxy-3-amino-3-phenyl-propionate (2) in n-Propanol:**




81.1 g, m.p. 147-148 °C  
(69% yield, 82% ee)

To a solution of (DHQ)<sub>2</sub>-PHAL (2.20 g, 2.80 mmol, 5 mol%) in n-Propanol (100 mL) and water (100 mL) in 500 mL Erlenmeyer or round-bottomed flask were added in order, methyl cinnamate (9.08 g, 56.0 mmol),

- 24 -

Chloramine-T trihydrate (48.4 g, 0.168 mol, 3.0 eq) and  
K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> (0.824 g, 2.24 mmol, 4 mol%). The reaction  
flask was immersed in a room-temperature water bath and  
the slurry stirred for 3 hr. Over the course of the  
5 reaction, the color changed from brown to deep green  
and then back to yellow as hydroxysulfonamide product  
appeared as white precipitates. The flask was then  
immersed in an ice bath (0 °C) for 20 min. During this  
cooling, almost all of crystalline hydroxysulfonamide  
10 product precipitated from the reaction solution. The  
product was isolated by filtration and the crude solid  
was washed once with cold (ca 5 °C) 1:1 n-  
Propanol/H<sub>2</sub>O (15 mL) to yield 11.7 g of (2R,3S)-(+)-  
methyl-N-(p-toluenesulfonyl)-2-hydroxy-3-amino-3-phenyl  
15 propionate (60% yield, 89% ee).


**Synthesis of (2R,3S)-2-hydroxy-3-amino-3-phenylpropionic acid (3); (figure 3)**



**Compound 3.** A heavy-walled borosilicate pressure bottle was charged with the enantiomerically enriched (92% ee) 2 [i.e. the triturated but not recrystallized material (vide supra)] (1.25 g, 3.6 mmol), phenol (1.04 g, 11.1 mmol) and excess 33% hydrogen bromide in acetic acid (20 mL, 0.117 mol, Acros). The bottle was sealed with a bushing, having a Teflon-lined cap, before being immersed completely in an oil bath. The bath was maintained at 75 °C for 10-12 h. The resulting solution was then concentrated in vacuo to about 10 mL (water pump followed by an oil pump which was protected by a 0 °C aqueous KOH bubbler). The crude solution was purified by ion-exchange chromatography (Amberlite IR-120 resin, 35 g), eluting with 80 mL of water (to remove impurities), then with 80 mL of 10% ammonium hydroxide (start with a dilute solution due the heat generated in the ion exchange process) followed by 80 mL of 40% ammonium hydroxide. Collection of the ammonium hydroxide eluate gave a solution of the ammonium salt of 3 which upon lyophilization yielded pure (2R,3S)-2-hydroxy-3-amino-3-phenylpropionic acid

(37, 0.51 g, 77%). m.p. 235 °C, decomp. (literature: Deng et. al J. Org. Chem. 57, (1992), 4320: m.p. 238 °C, decomp.); rotation after conversion to the hydrochloride salt is  $[\alpha]_D^{25} = -14.5^\circ$  (c 0.37, MeOH;  $[\alpha]_D^{25} -15.1^\circ$  c 0.365, MeOH). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O)  $\delta$  4.09 (d, J = 6.0 Hz, 1H), 4.32 (d, J = 6.0 Hz, 1H), 7.21-7.41 (m, 5H); <sup>13</sup>C NMR (100 MHz, D<sub>2</sub>O/DMSO)  $\delta$  177.7, 135.4, 130.9, 130.7, 128.9, 75.0, 59.0.

**N-Benzoyl-(2R,3S)-2-hydroxy-3-amino-3-phenylpropionic Acid (4); figure 3.**



**4**  
65%

**Compound 4.** The enantiomerically enriched 37 (0.43 g, 2.37 mmol) was converted to N-benzoyl-(2R,3S)-2-hydroxy-3-amino-3-phenylpropionic acid (4, 0.44 g, 65%) according to our earlier Schotten-Baumann-based procedure for this same transformation (Sharpless et

- 27 -

al. J. Org. Chem. 59 (1994), 5104). Chemically and enantiomerically pure 4 was isolated by simple filtration of the solid which appeared when the pH of the reaction mixture was adjusted to ca. 2 by addition of aqueous HCl. m.p. 166-167 °C (lit: Ojima et al. J. Org. Chem 56 (1991) 1681: 167-169 °C);  $[\alpha]_D^{25}$  -34.0° (c 0.50, EtOH) (lit: Sharpless et al. J. Org. Chem. 1976, 41, 177:  $[\alpha]_D^{25}$  -35.9° c 0.565, EtOH); lit3d  $[\alpha]_D^{25}$  -35.5° (c 1.07, EtOH); <sup>1</sup>H NMR (400 MHz, DMSO) δ 4.37 (d, J = 4.3 Hz, 1H), 5.46 (dd, J = 8.8, 4.2 Hz, 1H), 7.22-7.55 (m, 9H), 7.84 (d, J = 7.2 Hz, 1H), 8.60 (d, J = 8.9 Hz, 1H), 12.73 (br, 1H); <sup>13</sup>C NMR (100 MHz, DMSO) δ 173.5, 166.0, 140.3, 134.4, 131.4, 128.4, 128.0, 127.4, 127.2, 126.9, 73.6, 55.8.

**General procedure 1 (Figure 4): Catalytic asymmetric aminohydroxylation in 1:1 acetonitrile/water (used for synthesis of compounds 2, 5, 6, 7, 8 or 9).** To a stirred solution of (DHQ)<sub>2</sub>-PHAL (0.11 g, 0.14 mmol, 5 mol%) in 20 mL of acetonitrile and 20 mL of water, in any convenient-sized glass vessel or vial, was added desired olefin (all commercially available from

- 28 -

Aldrich, **figure 4**, 2.8 mmol), Chloramine-T trihydrate (2.42 g, 8.4 mmol, 3 eq) and  $K_2OsO_2(OH)_4$  (41.6 mg, 0.112 mmol, 4 mol%). As the reaction proceeded to completion over the course of about one and half hours at room temperature, the color of the solution changed from yellow to pale green, then deep green and finally back to yellow (for entry 3 in Table 1, the yellow color remains throughout). After addition of aqueous sodium sulfite (1.0 g in 15 mL  $H_2O$ ), the phases were separated, and the aqueous phase extracted with ethyl acetate (3x15 mL). The combined organic extracts were washed with brine, dried over  $MgSO_4$  and the solvent concentrated to give the crude product, which also contains the p-toluenesulfonamide by-product produced upon the reduction of the excess Chloramine-T. In the case of the ethyl crotonate derivative, product **5**, flash chromatography (6:4:1 hexane/ $CHCl_3$ /MeOH) of this material provided 0.44 g (52% yield, 74% ee) of (2R,3S)-ethyl-N-(p-toluenesulfonyl)-2-hydroxy-3-amino-butanoate (**5**) as a clear oil eluting before the p-toluenesulfonamide impurity (52% yield, 74 % ee). Similar purification provides compounds **2**, **6**, **7**, **8** and

9. with the indicated yields and conditions shown in figure 4.

NOTE: Replacement of the 3 eq of Chloramine-T with 1.5 eq of Chloramine-T and 1.5 eq of Et<sub>4</sub>NOAc gives  
5 comparable results and reduces the amount of p-toluenesulfonamide by-product formed. This can greatly simplify product isolation, especially in cases where the product and the toluenesulfonamide have similar chromatographic mobilities.

10

**General Procedure 2 (Figure 6): Catalytic asymmetric aminohydroxylation in 1:1 tertbutanol/water (used for synthesis of compounds 2, 7 or 8).** To a solution of (DHQ)2-PHAL (2.20 g, 2.80 mmol, 5 mol%) in t-BuOH (100  
15 mL) and water (100 ml) in 500 mL Erlenmeyer or round-bottomed flask were added in order, desired olefin (56.0 mmol), Chloramine-T trihydrate (48.4 g, 0.168 mol, 3.0 eq) and K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> (0.824 g, 2.24 mmol, 4 mol%). The reaction flask was immersed in a room-  
20 temperature water bath and the slurry stirred for 2.5 hr. Over the course of the reaction, the color changed from brown to deep green and then back to yellow as the

- 30 -

stilbene slurry became a hydroxysulfonamide slurry. The product was isolated by filtration and the crude solid was washed once with cold (ca 5 °C) 1:1 t-BuOH/H<sub>2</sub>O (15 mL) to yield the product  $\beta$ -hydroxysulfonamide. In the case of product **7**, 16.1 g of N-(p-toluenesulfonyl)-(1S,2S)-2-amino-1,2-diphenylethanol (**7**) (78% yield, 64% ee, pure by NMR and HPLC). Trituration of this product twice with ethyl acetate (2x15 mL) at room temperature in a sintered glass funnel gave enantiomerically pure **7** (10.3 g, 50% yield, > 99% ee, mp 166-167 °C). See Sharpless, J. Org. Chem. 1994, 59, 5104 and Sharpless, J. Org. Chem. 1994, 59, 8302 for analogous solid-to-solid AD procedures.

**Analysis of enantiomeric excesses for 2-9.** Methyl cinnamate derivative **2**: Chiralcel OG, 30% i-PrOH/hexane, 1 mL/min; 21.8 min (2S,3R), 28.3 min (2R,3S). Ethyl crotonate derivative **5**: Chiralcel OD-H, 15% i-PrOH/hexane, 1 mL/min, 7.5 min (2S,3R), 13.4 min (2R,3S). Dimethyl fumarate derivative **6**: Chiralcel OG, 30% i-PrOH/hexane, 1 mL/min, 16.7 min (2S,3S), 21.8 min (2R,3R). trans-Stilbene derivative **5**: Chiralcel OD-H,




15% i-PrOH/hexane, 1 mL/min, 16.2 min (1S,2S), 26.0 min  
(1R,2R). cis-Stilbene derivative **8**: Chiralcel OD-H, 15%  
i-PrOH/hexane, 0.5 mL/min, 18.5 min (1S,2R), 22.1 min  
(1R,2S). Cyclohexene derivative **9**: Chiralcel OG, 15% i-  
5 PrOH/hexane, 0.5 mL/min, 28.5 min (1S,2R), 34.4 min  
(1R,2S).

**Correlation of the absolute configurations of 2-9.**

**Methyl cinnamate derivative (2R,3S)-2:** Authentic  
10 (2R,3S)-2 was synthesized from N-benzoyl-(2R,3S)-3-  
phenylisoserine methyl ester (Taxol C-13 side chain;  
synthesis provided from Collet et al, Ecole normal  
superiure de Lyon, private communication) [6N HCl,  
reflux (remove methyl ester and N-benzoyl); SOCl<sub>2</sub>,  
15 methanol (esterification); TsCl, K<sub>2</sub>CO<sub>3</sub>, 1:1  
acetone/water (N-sulfonylation)] [HPLC: vide supra].


- 32 -

**Ethyl crotonate derivative (2R,3S)-5:**

5

**Compound 5:** (2R,3S)-5 was converted to N-tosyl-(2S)-alanine methyl ester [6N HCl (hydrolysis); RuCl<sub>3</sub>/H<sub>5</sub>IO<sub>6</sub> (oxidative cleavage); SOCl<sub>2</sub>, methanol (esterification)] [HPLC: Chiralcel OD-H, 15% i-PrOH/hexane, 1 mL/min, 16.1 min (2R), 17.0 min (2S)].

10

**Dimethyl fumarate derivative (2R,3R)-6:**


15

**Compound 6:** (2R,3R)-6 was converted to its N-tosyl-(2R,3R)-2-oxazolidinone derivative which was independently synthesized from (1S,2S)-7 [carbonyl diimidazole, CH<sub>2</sub>Cl<sub>2</sub>; RuCl<sub>3</sub>, H<sub>5</sub>IO<sub>6</sub> (oxidative degradation of the phenyl groups); (Polt et. al. *J. Org. Chem.* **1992**, 57, 5469), SOCl<sub>2</sub>, methanol (esterification)] [HPLC:

20


Chiralcel OD-H, 15% i-PrOH/hexane, 1 mL/min, 26.0 min  
(1R,2R), 47.2 min (1S,2S)].

**trans-Stilbene derivative (1S,2S)-7:**




**Compound 7:** An authentic sample of (1S,2S)-7 was  
synthesized from (1R,2S)-8 [CrO<sub>3</sub>, H<sub>2</sub>SO<sub>4</sub> (alcohol to  
10 ketone); DIBAL-H reduction gave a 4:1 mixture of  
(1R,2S)-8 to (1S,2S)-7] [HPLC: vide supra].

**cis-Stilbene derivative (1S,2R)-8:**



**Compound 8:** An authentic sample of (1R,2S)-8 was  
synthesized from (1R,2S)-2-amino-1,2-diphenylethanol  
[TsCl, K<sub>2</sub>CO<sub>3</sub>, acetone/water] [HPLC: vide supra].

20 **Cyclohexene derivative (1S,2R)-9:**



- 34 -

**Compound 9:** N,N'-ditosyl-(1R,2R)-diaminocyclohexane was synthesized from (1S,2R)-7 [SO<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, EtOAc; NaH (cyclic sulfamidate formation); NaN<sub>3</sub> (opening); H<sub>2</sub>, Pd/C (azide reduction); TsCl, K<sub>2</sub>CO<sub>3</sub>, 1:1 acetone/water] and compared to the compound derived from authentic (1R,2R)-diaminocyclohexane [22] [HPLC: Chiralcel AS, 20% i-PrOH/hexane, 1 mL/min, 23.2 min (1R,2R), 32.3 min (1S,2S)].


**Catalytic asymmetric aminohydroxylation in 1:1 tertbutanol/water (used for synthesis of compounds 2, 13, 15, 23, 25 or 27) as illustrated in FIGURE 8.**

**Compounds 2, 13, 15, 23, 25 or 27.** To a solution of (DHQ)<sub>2</sub>-PHAL (2.20 g, 2.80 mmol, 5 mol%) in t-BuOH (100 mL) and water (100 mL) in 500 mL Erlenmeyer or round-bottomed flask were added in order, desired olefin (methyl cinnamate, p-methoxy-methyl-cinnamate **12**, p-bromo-ethyl-cinnamate **14**, o-methyl-methyl-cinnamate **22**, 2,5-dimethyl-methyl-cinnamate **24** or 2,5-dimethoxy-methyl-cinnamate **26**; all commercially available from Aldrich) (56.0 mmol), Chloramine-T trihydrate (48.4 g,

- 35 -

0.168 mol, 3.0 eq) and  $K_2OsO_2(OH)_4$  (0.824 g, 2.24 mmol, 4 mol%). The reaction flask was immersed in a room-temperature water bath and the slurry stirred for 2.5 hr. Over the course of the reaction, the color changed from brown to deep green and then back to yellow as the stilbene slurry became a hydroxysulfonamide slurry. The product was isolated by filtration and the crude solid was washed once with cold (ca 5 °C) 1:1 t-BuOH/H<sub>2</sub>O (15 mL) to yield the product  $\beta$ -hydroxysulfonamide. Trituration of this product twice with ethyl acetate (2x15 mL) at room temperature in a sintered glass funnel gave enantiomerically pure  $\beta$ -hydroxysulfonamide compounds 2, 13, 15, 23, 25 or 27.

Catalytic asymmetric aminohydroxylation in 1:1:1 ethanol/n-propanol/water (used for synthesis of compound 11) as illustrated in FIGURES 7 and 8.



11: 94%ee  
Regioselectivity: 31:1  
Yield: 86%

- 36 -

To a solution of (DHQ)<sub>2</sub>-PHAL (2.20 g, 2.80 mmol, 5 mol%) in ethanol (63 mL) n-Propanol (63 mL) and water (63 mL) in 500 mL Erlenmeyer or round-bottomed flask were added in order, commercially available p-nitro methyl cinnamate derivative (**10**; Aldrich chemical company) (9.08 g, 56.0 mmol), Chloramine-T trihydrate (48.4 g, 0.168 mol, 3.0 eq) and K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> (0.824 g, 2.24 mmol, 4 mol%). The reaction flask was immersed in a room-temperature water bath and the slurry stirred for 5 hr. Over the course of the reaction, the color changed from brown to deep green and then back to yellow as hydroxysulfonamide product appeared as white precipitates. The flask was then immersed in an ice bath (0 °C) for 20 min. During this cooling, almost all of crystalline hydroxysulfonamide product precipitated from the reaction solution. The product was isolated by filtration and the crude solid was washed once with cold (ca 5 °C) 1:1 n-Propanol/H<sub>2</sub>O (15 mL) to yield enantiomerically pure β-hydroxysulfonamide compound **11** in 86% overall yield and 94% ee.

**Catalytic asymmetric aminohydroxylation in 1:1 n-**

propanol/water (used for synthesis of compounds 17, 19, 21, 23 or 25) as illustrated in FIGURE 8.


Compounds 17, 19, 21, 23 or 25. To a solution of (DHQ)<sub>2</sub>-PHAL (2.20 g, 2.80 mmol, 5 mol%) in n-Propanol (100 mL) and water (100 ml) in 500 mL Erlenmeyer or round-bottomed flask were added in order, commercially available methyl or ethyl cinnamate derivatives (16, 18, 20, 22 or 24; Aldrich chemical company) (9.08 g, 56.0 mmol), Chloramine-T trihydrate (48.4 g, 0.168 mol, 3.0 eq) and K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> (0.824 g, 2.24 mmol, 4 mol%).

The reaction flask was immersed in a room-temperature water bath and the slurry stirred for 3 hr. Over the course of the reaction, the color changed from brown to deep green and then back to yellow as

hydroxysulfonamide product appeared as white precipitates. The flask was then immersed in an ice bath (0 °C) for 20 min. During this cooling, almost all of crystalline hydroxysulfonamide product precipitated from the reaction solution. The product was isolated by filtration and the crude solid was washed once with cold (ca 5 °C) 1:1 n-Propanol/H<sub>2</sub>O (15 mL) to yield enantiomerically pure β-hydroxysulfonamide

compounds 17, 19, 21, 23 or 25.

**Preparation of sulfonamides from sulfonylchlorides (as illustrated in figure 9 and 13)**



The sulfonyl chlorides used in the formation of the sulfonamides can come from commercially available sources such as Aldrich, Fluka, Sigma etc., or can be prepared from a procedure developed by Campbell et al. *Chem Rev.* **1978**, 78, 65, for the preparation of N-chloro-N-sodiocarbamates which is a general procedure in the synthesis of N-chloro-N-sodio-aryl-and alkylsulfonamides. The sulfonyl chlorides (R-SO<sub>2</sub>Cl) formed can include compounds where R = 4-Me-Ph-, 4-MeOPh, Me, Ph-CH<sub>2</sub>-, 4-NO<sub>2</sub>-Ph-, 2-NO<sub>2</sub>-Ph-, 2-Naphthyl, 1-Naphthyl, Dansyl (**figure 9 and 12**) or derivatives selected from the following functional groups: acyclic or cyclic hydrocarbons, hydroxyl compounds, ethers, protected amines, carbonyl compounds, esters or carboxylic acids, n-alkyl, alkynes (**60**) pyrans, pyrroles (**54**), various heterocycles including: nitriles (**58**), pyrazines,



pyrazoles (55), pyridazines, pyridines (57), pyrimidines (59), pyrrolizines, quinazolines, quionlines, thiophenes, silanes,  $\text{CH}_n\text{X}$  where  $\text{X}=\text{OR}_1$ , halogens, aromatic rings, heterocycles, silyl groups and  $n=1$  to 2 (56) (figure 13).

**Method A: using a sulfonyl chloride (as obtained supra) and gaseous  $\text{NH}_3(\text{g})$  (figure 9)**

$\text{NH}_3$  was bubbled (fritte or pipette) through well stirred  $\text{CH}_2\text{Cl}_2$  (ca 100 ml) at RT. The sulfonyl chloride (100 mmol) was added in portions. After all of the sulfonyl chloride was added, stirring at RT under  $\text{NH}_3$  was continued until TLC [hexane/ethylacetate] showed full conversion of the starting material. Precipitated  $\text{NH}_4\text{Cl}$  was filtered off, the solvent was evaporated ( $\text{NH}_3$ ) and the residue was crystallized from hot acetone / water and dried at high vacuum (oil pump, 0.1 - 0.01 torr) overnight to yield the crystalline, pure sulfonamides in nearly quantitative yields.


**Method B: using a sulfonyl chloride (as obtained supra) and aqueous ammonia (figure 9)**

- 40 -

The sulfonylchloride (100 mmol) was added portionwise to a well stirred aqueous solution (100 ml) of NH<sub>3</sub> (29.7 %. Fisher) at RT. After all of the sulfonyl chloride was added, stirring at RT was continued for 2  
5 more hours. The reaction mixture was slowly (NH<sub>3</sub>!) heated to reflux and then cooled down to ca 4 C. The precipitated product was filtered off and crystallized from hot acetone / water and dried at high vacuum (oil pump, 0.1 - 0.01 torr) overnight to yield the  
10 crystalline, pure sulfonamides in nearly quantitative yields.

Trimethylsilylethyl sulfonamide and related alkylsilyl-  
sulfonamides can be prepared according to a literature  
15 procedure: Steven M. Weinreb et al. Tetrahedron Lett. 1986, 27, 2099-2102.

**General catalytic asymmetric aminohydroxylation by in situ generation of chloramines different from**  
20 **Chloramine T**  
**(in situ generation of R-SO<sub>2</sub>NClNa) as illustrated in figure 10.**



5     **General procedure:** T-butyl hypochlorite was slowly  
 added to a well stirred solution of the desired  
 sulfonamide (as obtained *vide supra*; 3.1 mmol, 3.1 eq)  
 and 122 mg (3.05 mmol, 3.05 eq) of NaOH in 7.5 ml of  
 water at room temperature. After 10 more minutes of  
 10    stirring this solution was added dropwise to a solution  
 of 40 mg (0.05 mmol, 0.05 eq) of (DHQ)<sub>2</sub>Phal or  
 (DHQD)<sub>2</sub>Phal in 7.5 ml of MeCN (alternatively, a 1:1 mix  
 of t-BuOH/water, n-propanol/water or 1:1:1 ethanol/n-  
 proanol/water can be used, depending upon optimization  
 15    conditions). Subsequently 190 mg (1.0 mmol, 1.0 eq) of  
 olefin where **R**<sub>1</sub> = acyclic or cyclic hydrocarbons,  
 heterocycles, hydroxyl compounds, ethers, protected  
 amines, sulfides, carbonyl compounds, acrylates,  
 substituted acrylates, esters or carboxylic acids.

20    **R**<sub>2</sub> = combination of **R**<sub>1</sub>


**R**<sub>3</sub> = 4-Me-Ph-, 4-MeOPh, Me, Ph-CH<sub>2</sub>- , 4-NO<sub>2</sub>-Ph-, 2-NO<sub>2</sub>-  
 Ph-, 2-Naphthyl, 1-Naphthyl, Dansyl or derivatives

selected from the following functional groups: acyclic or cyclic hydrocarbons, hydroxyl compounds, ethers, protected amines, carbonyl compounds, esters or carboxylic acids, n-alkyl, pyrans, pyrroles, various heterocycles including: pyrazines, pyrazoles, pyridazines, pyridines, pyrimidines, pyrrolizines, quinazolines, quionlines, thiophenes, silanes,  $\text{CH}_n\text{X}$  where  $\text{X}=\text{OR}_1$ , halogens, aromatic rings, heterocycles, silyl groups and  $n=1$  to 2 (reagents commercially or synthetically available) and 14.7 mg (0.04 mmol, 0.04 eq) of  $\text{K}_2\text{OsO}_2(\text{OH})_4$  were added and the reaction mixture stirred at RT. After ca. 10 min all of the  $\text{K}_2\text{OsO}_2(\text{OH})_4$  was dissolved and the color of the reaction mixture turned to green. Stirring was continued until the green color of the reaction mixture had turned to yellow. 10 ml of aqueous  $\text{Na}_2\text{SO}_3$  (sat.) were added to reduce excess Chloramine. The aqueous phase was separated and extracted three times with ca. 30 ml ethyl acetate. The combined organic phases were washed with brine containing 1 % of NaOH, dried over  $\text{MgSO}_4$  (anhydrous) and the solvent was evaporated in vacuo. The residue was purified by flash chromatography ( $\text{SiO}_2$ ,

hexane/ethyl acetate) to afford the pure crystalline aminohydroxylation product. In cases where regioisomeric products could be formed yields refer to a mixture of the two regioisomeres. Crystallization from ethyl acetate/ hexane furnished the enantiomerically pure (>99 %ee) N-aryl/alkylsulfonyl protected amino alcohol (**figure 10**)

**Catalytic asymmetric aminohydroxylation of compounds 28-47 by in situ generation of chloramines different from Chloramine T**

(1 mmol scale, in situ generation of R-SO<sub>2</sub>NClNa) as illustrated in figure 11 and tabulated in figure 12.



20 **General procedure:** T-butyl hypochlorite was slowly added to a well stirred solution of the desired sulfonamide (as obtained *vide supra*; 3.1 mmol, 3.1 eq)


- 44 -

and 122 mg (3.05 mmol, 3.05 eq) of NaOH in 7.5 ml of water at room temperature. After 10 more minutes of stirring this solution was added dropwise to a solution of 40 mg (0.05 mmol, 0.05 eq) of (DHQ)<sub>2</sub>Phal or (DHQD)<sub>2</sub>Phal in 7.5 ml of MeCN (alternatively, a 1:1 mix of t-BuOH/water, n-propanol/water or 1:1:1 ethanol/n-propanol/water can be used, depending upon optimization conditions). Subsequently 190 mg (1.0 mmol, 1.0 eq) of isopropyl cinnamate (commercially available from Aldrich) and 14.7 mg (0.04 mmol, 0.04 eq) of K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> were added and the reaction mixture stirred at RT. After ca. 10 min all of the K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> was dissolved and the color of the reaction mixture turned to green. Stirring was continued until the green color of the reaction mixture had turned to yellow.

10 ml of aqueous Na<sub>2</sub>SO<sub>3</sub> (sat.) were added to reduce excess Chloramine. The aqueous phase was separated and extracted three times with ca. 30 ml ethyl acetate. The combined organic phases were washed with brine containing 1 % of NaOH, dried over MgSO<sub>4</sub> (anhydrous) and the solvent was evaporated in vacuo. The residue was purified by flash chromatography (SiO<sub>2</sub>,

hexane/ethyl acetate) to afford the pure crystalline aminohydroxylation product. In cases where regioisomeric products could be formed yields refer to a mixture of the two regioisomeres. Crystallization from ethyl acetate/ hexane furnished the enantiomerically pure (>99 %ee) N-aryl/alkylsulfonyl protected amino alcohol.

**Preparation of the Chloramine M: 48 ( $\text{CH}_3\text{SO}_2\text{NCl}$ )**



Chloramine M can be synthesized readily from methanesulfonamide (Aldrich chemical company) by addition of the stoichiometric amount of sodium hydroxide and t-butylhypochlorite in water or methanol. This method was adapted from a procedure developed by Campbell et al. *Chem Rev.* **1978**, 78, 65, for the preparation of N-chloro-N-sodiocarbamates and proved to be general in the synthesis of N-chloro-N-sodio-aryl- and alkylsulfonamides. Chloramine M can be isolated

- 46 -

either as a stable salt or can be prepared in situ,  
preferable in large scale syntheses.

**Synthesis of chloramine M:** To an ice-cold stirred  
solution of 4.81 g (50 mmol) of methanesulfonamide and  
5 2.0 g (50 mmol) sodium hydroxide in 40 mL of dry  
methanol is added very slowly 5.63 mL (5.4 g, 50 mmol)  
t-butylhypochlorite. The solution is stirred for 1h and  
dried in vacuo to afford the pure N-chloro,N-sodio-  
methanesulfonamide in quantitative yield (7.58 g).

10  $\text{CH}_3\text{NSO}_2\text{NaCl}$ , MW: 151.54; Elementary analysis: calcd.: C  
7.93, H 2.00, N 9.24, Na 15.17, Cl 23.39 found: C 8.03,  
H 2.08, N 9.24, Na 15.36, Cl 23.12

For the in situ generation of Chloramine M the  
preparation can be done in the sufficient amount of  
15 water required for the AA reaction by using the same  
protocol.

**General procedure for synthesis of hydroxysulfonamides  
using Chloramine M ( $\text{MeSO}_2\text{NClNa}$ ) on a 1 mmol scale (as  
20 illustrated in figure 14 and tabulated in figure 15)**

To a well stirred solution of 40 mg of  $(\text{DHQD})_2\text{PHAL}$   
(0.05 mmol, 0.05 eq) in 7.5 ml of n-propanol



- 47 -

(alternatively, a 1:1 mix of t-BuOH/water, acetonitrile/water or 1:1:1 ethanol/n-proanol/water can be used, depending upon optimization conditions) was slowly added a solution of 455 mg (3.0 mmol, 3.0 eq) of MeSO<sub>2</sub>NClNa in 7.5 ml of water, which resulted in a clear colorless solution. The substrate olefin (all commercially available from Aldrich, **figure 15**, 1.0 mmol, 1.0 eq ) and K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> (0.04 mmol, 0.04 eq) were subsequently added. Usually the reaction mixture turned green after some minutes and was stirred until color change to dark blue occurred (3-16 h), however colour changes are not generally observed. 10 ml of aqueous Na<sub>2</sub>SO<sub>3</sub> (sat.) were added to reduce the excess MeSO<sub>2</sub>NClNa. The aqueous phase was separated and extracted three times with ca. 30 ml ethyl acetate. The combined organic phases were dried over MgSO<sub>4</sub> (anhydrous) and the solvent was evaporated in vacuo. To determine the exact yield the residue was purified by flash chromatography (SiO<sub>2</sub>, hexane/ethyl acetate) to afford the pure crystalline aminohydroxylation product. In cases where regioisomeric products can be formed yields refer to a mixture of the two regioisomers.


Crystallization from ethyl acetate/ hexane furnished the enantiomerically pure (>99 %ee) methane sulfonyl protected amino alcohol.

For preparative purposes work-up and purification can be simplified. As the methanesulfonamide is insoluble in CH<sub>2</sub>Cl<sub>2</sub> and ether, but good soluble in aqueous solution (even in saturated aqueous NaCl solution) it can be removed extractively. It can also be crystallized out in CH<sub>2</sub>Cl<sub>2</sub> or CH<sub>2</sub>Cl<sub>2</sub>/hexane mixtures.

Alternatively it can be sublimed from the crude material at 80°C. Crystallization from ethyl acetate/ hexane could usually furnish the chemically and enantiomerically pure (>99 %ee) methane sulfonyl protected amino alcohol.

**Asymmetric aminohydroxylation in 1:1 acetonitrile/water (used for synthesis of acrylates and methacrylates as shown in figures 16 and 17).**

20



To a stirred solution of (DHQ)<sub>2</sub>-PHAL (0.11 g, 0.14 mmol, 5 mol%) in 20 mL of acetonitrile and 20 mL of water, in any convenient-sized glass vessel or vial, was added desired acrylate or methacrylates entries 1-10 (all commercially available from Aldrich, **figure 16** and **figure 17**, 2.8 mmol), Chloramine-T trihydrate (2.42 g, 8.4 mmol, 3 eq) and K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> (41.6 mg, 0.112 mmol, 4 mol%). As the reaction proceeded to completion over the course of about one and half hours at room temperature, the color of the solution changed from yellow to pale green, then deep green and finally back to yellow. After addition of aqueous sodium sulfite (1.0 g in 15 mL H<sub>2</sub>O), the phases were separated, and the aqueous phase extracted with ethyl acetate (3x15 mL). The combined organic extracts were washed with brine, dried over MgSO<sub>4</sub> and the solvent concentrated to give the crude product, which also contains the p-toluenesulfonamide by-product produced upon the reduction of the excess Chloramine-T. Purification provides compounds as shown in figure 16, entries 1-10 with the indicated yields and conditions.


NOTE: Replacement of the 3 eq of Chloramine-T with 1.5

- 50 -

eq of Chloramine-T and 1.5 eq of Et<sub>4</sub>NOAc gives comparable results and reduces the amount of p-toluenesulfonamide by-product formed. This can greatly simplify product isolation, especially in cases where  
5 the product and the toluenesulfonamide have similar chromatographic mobilities.

---

General procedure for synthesis of compound 2 (figure 18):



**Compound 2:** T-butyl hypochlorite was slowly added to a well stirred solution of the desired sulfonamide (as obtained *vide supra*; 3.1 mmol, 3.1 eq) and 122 mg (3.05 mmol, 3.05 eq) of NaOH in 7.5 ml of water at room temperature. After 10 more minutes of stirring this solution was added dropwise to a solution of 40 mg (0.05 mmol, 0.05 eq) of (DHQ)<sub>2</sub>Phal or (DHQD)<sub>2</sub>Phal in 7.5 ml of MeCN (alternatively, a 1:1 mix of t-BuOH/water, n-propanol/water or 1:1:1 ethanol/n-propanol/water can be used, depending upon optimization conditions). Subsequently 190 mg (1.0 mmol, 1.0 eq) of methyl cinnamate (commercially available from Aldrich) and 14.7 mg (0.04 mmol, 0.04 eq) of K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> were added and the reaction mixture stirred at RT. After ca. 10 min all of the K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> was dissolved and the color of the reaction mixture turned to green. Stirring


- 52 -

was continued until the green color of the reaction mixture had turned to yellow.

10 ml of aqueous  $\text{Na}_2\text{SO}_3$  (sat.) were added to reduce excess Chloramine. The aqueous phase was separated and  
5 extracted three times with ca. 30 ml ethyl acetate. The combined organic phases were washed with brine containing 1 % of NaOH, dried over  $\text{MgSO}_4$  (anhydrous) and the solvent was evaporated in vacuo. The residue was purified by flash chromatography ( $\text{SiO}_2$ ,  
10 hexane/ethyl acetate) to afford the pure crystalline aminohydroxylation product. In cases where regioisomeric products could be formed yields refer to a mixture of the two regioisomeres. Crystallization  
from ethyl acetate/ hexane furnished the  
15 enantiomerically pure (>99 %ee) N-aryl/alkylsulfonyl protected amino alcohol.

Synthesis of  $\beta$ -hydroxy- $\alpha$ -N-aryl/alkylsulfonyl protected aminoacids 62 or 63 via aziridine intermediate 61

(figure 18):



**Compounds 62 and 63:** To the AA product 2 (2.15 mmol), in a THF solution (0.10 M), was added  $\text{P}(\text{Ph})_3$  (1.1 equivalents triphenylphosphine) and diethyl azodicarboxylate (1.1 equivalents, all commercially available from Aldrich). The mixture was next stirred at room temperature for 1 hour and then worked up according to the procedure of Mitsunobu et al. *Tetrahedron Letters*, **1989**, 5709. The resulting aziridine (0.302 mmol) was dissolved in a 6:4 v/v mixture of 1,4-dioxane/ $\text{H}_2\text{O}$  and 0.03 mL of TFA (trifluoroacetic acid) was added as the catalyst. The reaction was then run at 100 °C for 24 °C. The mixture was diluted with ethylacetate and separated from the aqueous phase. The aqueous phase was separated and extracted three times with ca. 30 ml ethyl acetate. The

combined organic phases were washed with brine containing 1 % of NaOH, dried over MgSO<sub>4</sub> (anhydrous) and the solvent was evaporated in vacuo. The residue was purified by flash chromatography (SiO<sub>2</sub>, hexane/ethyl acetate) to afford the pure crystalline aminohydroxylation product. In case where regioisomeric products are formed, crystallization from ethyl acetate/ hexane furnishes the enantiomerically pure (>99 %ee) β-hydroxy-α-N-aryl/alkylsulfonyl protected aminoacid **62** or **63**.



What is claimed is:


1. An improved method for converting an olefinic substrate to an asymmetric hydroxylamine product by asymmetric addition of a nitrogen source and a hydroxyl radical to the olefinic substrate, the method being of a type which employs a reaction solution which includes osmium as a catalyst, a chiral ligand for enantiomerically directing said asymmetric addition, the olefinic substrate being present and soluble at a stoichiometric concentration within the reaction solution, the osmium being present and soluble within the reaction solution at a catalytic concentration,

wherein the improvement comprises the following substeps:

Substep A: said asymmetric addition is performed using a sulfonamide as the nitrogen source for forming an asymmetric hydroxysulfonamide intermediate; and then:

Substep B: said conversion is completed by deprotecting the asymmetric hydroxysulfonamide intermediate in said Substep A for forming the asymmetric hydroxylamine product.

2. A method for converting an olefinic substrate to an asymmetric hydroxylamine product as described in claim 1 wherein the sulfonamide is represented by the following structures:




wherein R is a radical selected from the group consisting of cyano, phenyl, 4-methyl-phenyl-, 4-methyl-O-phenyl-, methyl-, phenyl-CH<sub>2</sub>-, 4-NO<sub>2</sub>-phenyl-, 2-NO<sub>2</sub>-phenyl-2-naphthyl-, 1-naphthyl-, dansyl-, -O-(C<sub>1-6</sub>-alkyl), pyrrole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrolizine, quinazoline, quionline, thiophene and -(CH<sub>2</sub>)<sub>n</sub>-X wherein X is a radical selected from the group consisting of chloride, fluoride, iodide, phenyl, 4-methyl-phenyl-, 4-methyl-O-phenyl-, methyl-, phenyl-CH<sub>2</sub>-, 4-NO<sub>2</sub>-phenyl-, 2-NO<sub>2</sub>-phenyl-2-naphthyl-, 1-naphthyl-, dansyl-, pyrrole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrolizine, quinazoline, quionline and thiophene, wherein 1 ≤ n ≤ 6.

3. A method for converting an olefinic substrate to an asymmetric hydroxysulfonamide product comprising the step of:

catalyzing an asymmetric addition to the olefinic substrate of a sulfonamidyl radical and a hydroxyl radical by means of an osmium catalyst, said catalysis occurring in the presence of a chiral ligand for enantiomerically directing the asymmetric addition.

4. A method for converting an olefinic substrate to an asymmetric hydroxylamine product as described in claim 3 wherein the sulfonamide is represented by the following structures:



15 wherein R is a radical selected from the group consisting of cyano, phenyl, 4-methyl-phenyl-, 4-methyl-O-phenyl-, methyl-, phenyl-CH<sub>2</sub>-, 4-NO<sub>2</sub>-phenyl-, 2-NO<sub>2</sub>-phenyl-2-naphthyl-, 1-naphthyl-, dansyl-, -O-(C<sub>1-6</sub>-alkyl), pyrrole, pyrazine, pyrazole, pyridazine, 20 pyridine, pyrimidine, pyrrolizine, quinazoline, quionline, thiophene and -(CH<sub>2</sub>)<sub>n</sub>-X wherein X is a radical selected from the group consisting of chloride, fluoride, iodide, phenyl, 4-methyl-phenyl-, 4-methyl-O-phenyl-, methyl-, phenyl-CH<sub>2</sub>-, 4-NO<sub>2</sub>-phenyl-, 2-NO<sub>2</sub>-phenyl-2-naphthyl-, 1-naphthyl-, dansyl-, pyrrole, 25 pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrolizine, quinazoline, quionline and thiophene, wherein 1 ≤ n ≤ 6.

30 5. A method for converting an olefinic substrate to an asymmetric hydroxysulfonamide product as described in claim 3 wherein the sulfonamide is a chloramine compound.

5 6. A method for converting an olefinic substrate to an asymmetric hydroxysulfonamide product as described in claim 3 wherein said asymmetric addition occurs in a co-solvent mixture containing an organic component and an aqueous component.

10 7. A method for converting an olefinic substrate to an asymmetric hydroxysulfonamide product as described in claim 6 wherein the organic component of the solvent is selected from the group consisting of acetonitrile, tert-butanol, and n-propanol.

15 8. A method for converting an olefinic substrate to an asymmetric hydroxysulfonamide product as described in claim 6 wherein the aqueous and organic components of the co-solvent are each approximately 50% on a volume basis.

20 9. A method for converting an olefinic substrate to an asymmetric hydroxysulfonamide product as described in claim 3 wherein said catalysis occurs substantially in the absence of an ancillary metal salt.

25 10. A method for converting an olefinic substrate to an asymmetric hydroxysulfonamide product as described in claim 9 wherein the ancillary metal salt is selected from the group consisting of silver salts and mercury salts.




FIG. 1

2 / 19




FIG. 2

3 / 19
















FIG. 3

4 / 19

Entry	Substrate	Product [o]	%ee			Time(h)	m.p.(°C)[b]	$[\alpha]_D^{25}$ [b]
			(DHQD) <sub>2</sub> -PHAL [b]	(DHQD) <sub>2</sub> -PHAL [c]	(DHQD) <sub>2</sub> -PHAL [c]			
1			81 (99)	71	64	3	154-155	+19.8 (c=0.50)
2			74	60	52	1.5	oil	-20.3 (c=1.25)
3			77 (93)	53	65	3	140-141	-7.9 (c=0.63)
4[d]			62 (99)	50	52	14	167-168	-15.9 (c=0.43)
5			33 (99)	48	48	3	227-228	+53.0 (c=0.11)
6			45 (99)	36	64	6	117-119	+1.8 (c=0.60)

SUBSTITUTE SHEET (RULE 26)

FIG 4






FIG. 5








Substrate	Product	%ee (DHQ) <sub>2</sub> -PHAL	Yield (%)	Time (h)
		82(89 [a])	60(51 [a])	3
		64(99 [b])	78(50 [b])	3
		50	57	2.5

FIG. 6



Conditions:

5% (DHQD)<sub>2</sub>PHAL  
4% K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub>  
3 eq TsNCINa · 3H<sub>2</sub>O  
EtOH(5)/*n*-Propanol(3)/H<sub>2</sub>O(5)  
Room temperature, 5 hr

FIG. 7




FIG. 8A

9 / 19




FIG.8B





FIG. 8C


11 / 19



$\text{R} = 4\text{-Me-Ph-}, 4\text{-MeOPh}, \text{Me}, \text{Ph-CH}_2^-, 4\text{-NO}_2\text{-Ph-}, 2\text{-NO}_2\text{-Ph-}$   
 $2\text{-Naphthyl}, 1\text{-Naphthyl}, \text{Dansyl}$  or derivatives selected from the following functional groups:  
 acyclic or cyclic hydrocarbons, hydroxyl compounds, ethers, protected amines,  
 carbonyl compounds, esters or carboxylic acids, *n*-alkyl, pyrans, pyrroles, various  
 heterocycles including: pyrazines, pyrazoles, pyridazines, pyridines,  
 pyrimidines, pyrrolizines, quinazolines, quionilines, thiophenes, silanes,  $\text{CH}_n\text{X}$  where  
 $\text{X}=\text{OR}_1$ , halogens, aromatic rings, heterocycles, silyl groups and  $n=1$  to 2.

FIG. 9

12 / 19



$\text{R}_1$  = acyclic or cyclic hydrocarbons, heterocycles, hydroxyl compounds, ethers, protected amines, sulfides, carbonyl compounds, acrylates, substituted acrylates, esters or carboxylic acids


$\text{R}_2$  = combination of  $\text{R}_1$

$\text{R}_3$  = 4-Me-Ph-, 4-MeOPh, Me, Ph-CH<sub>2</sub>-, 4-NO<sub>2</sub>-Ph-, 2-NO<sub>2</sub>-Ph-  
 2-Naphthyl, 1-Naphthyl, Dansyl or derivatives selected from the following functional groups:  
 acyclic or cyclic hydrocarbons, hydroxyl compounds, ethers, protected amines,  
 carbonyl compounds, esters or carboxylic acids, n-alkyl, pyrans, pyrroles, various  
 heterocycles including: pyrazines, pyrazoles, pyridazines, pyridines,  
 pyrimidines, pyrrolizines, quinazolines, quionlines, thiophenes, silanes, CH<sub>n</sub>X where  
 X=OR<sub>1</sub>, halogens, aromatic rings, heterocycles, silyl groups and n=1 to 2.

FIG. 10



13 / 19



29;31;33;35;37  
39;41;43;45;47








28;30;32;34;36  
38;40;42;44;46

R = 4-Me-Ph-  
4-MeO-Ph-  
Me-  
Ph-CH2-  
TMS-CH2-CH2-  
4NO2-Ph -  
2-Naph.  
1-Naph.  
Dansyl

FIG. 11

	R-SO <sub>2</sub> -NH <sub>2</sub>	time [h]	%ee	regioselectivity	yield* [%]
28:29	4-Me-Ph-	2	66	80 : 20	
30:31	4-MeO-Ph-	2	58	65 : 35	
32:33	Me-	4	80	83 : 17	
34:35	Ph-CH <sub>2</sub> -	8	85	8 : 2	38
36:37	TMS-CH <sub>2</sub> -CH <sub>2</sub> -	2	70	83 : 17	48
38:39	4-NO <sub>2</sub> -Ph-	6	67	81 : 19	
40:41	2-NO <sub>2</sub> -Ph-	6	70	72 : 25	
42:43	2-Naph.	3	79		50
44:45	1-Naph.	4	62	96 : 4	
46:47	Dansyl	5	(50)	96 : 4	

FIG. 12



X = OR, Cl, aromatic rings .....

**FIG. 13**

16 / 19




FIG. 14


17 / 19

Substrate	Product	(DHQD) <sub>2</sub> -PHAL(DHQD) <sub>2</sub> -PHAL	Yield (%)	Time (h)	m.p. (°C)	[α] <sub>D</sub> <sup>25</sup> [c]
		%ee				
		(81)	(71)	(64)		
		(66)	(1)	(1)		
		95 (77)	94 (53)	63 (65)		
		75 (62)	82 (50)	71 (51)		
		80	82	63	16	116-117
		(45)	(36)	(64)		

FIG 15

18 / 19

# AA of Acrylates and Methacrylates




Entry	R	R'	ee [%] <sup>a</sup>
1	Me	H	42 (38)*
2	Et	H	46
3	<i>n</i> -Hexyl	H	47
4	<i>i</i> -Bu	H	40 (30)*
5	<i>c</i> -Hexyl	H	49.5
6	<i>t</i> -Bu	H	56 (37)*
7	<i>t</i> -Bu	H	70** (57)***
8	Stearyl	H	-
9	Me	Me	9
10	<i>t</i> -Bu	Me	32 (18)*

FIG 16

19 / 19

# AA of *t*-Butyl Acrylate



Std. Conditions		56 % ee, (54 %)
Std. Conditions	+ NaCl (heterogen.)	54 % ee
Std. Conditions	+ 0 °C	53 % ee
Std. Conditions	+ 1.5 eq. CT	53 % ee
Std. Conditions	+ 4 % "Os" + 2 % Ligand	50 % ee
Std. Conditions	+ <i>t</i> BuOH / H <sub>2</sub> O	56 % ee *
Std. Conditions	+ EtOH / H <sub>2</sub> O	16 % ee *
Std. Conditions	+ 0.5 % "Os" + 0.5 % Ligand	42% ee
Std. Conditions	+ 0.8 % "Os" + 1 % (DHQ) <sub>2</sub> .DPP Ligand	59 % ee
Std. Conditions	+ (DHQ) <sub>2</sub> -DPP Ligand	70 % ee

\* Low yield

Std. Conditions:

(DHQ)<sub>2</sub>PHAL (5 %), K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> (4 %) Chloramine T (3 eq.)

**FIG. 17**

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/08593

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07C 315/00

US CL : 562/12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 562/12

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
NoneElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
APS, CAS ONLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Catalytic Asymmetric Dihydroxylation of Tetrasubstituted Olefins, Journal of American Chemical Society, Vol. 115, No. 18 pages 8463-8464, Morikawa et al. See entire document.	1-10



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

10 SEPTEMBER 1997

Date of mailing of the international search report

23 OCT 1997

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SAMUEL BARTS

Telephone No. (703) 308-1235